

Clinical Laboratory HEMATOLOGY

Fourth Edition

Shirlyn McKenzie | Kristin Landis-Piwowar | Lynne Williams





Fourth Edition

Clinical Laboratory Hematology

Shirlyn B. McKenzie, PhD, MLS(ASCP)^{CM}, SH(ASCP)^{CM}
*Medical Laboratory Sciences, Department of Health Sciences, School of Health Professions
UT Health San Antonio*

Kristin Landis-Piwowar, PhD, MLS(ASCP)^{CM}
*Clinical and Diagnostic Sciences, School of Health Sciences
Oakland University*

J. Lynne Williams, PhD, MT(ASCP)
*Clinical and Diagnostic Sciences, School of Health Sciences
Oakland University*



Courseware Portfolio Manager, Health Sciences: John Goucher
Editorial Assistant: Cara Schaurer
Managing Content Producer: Melissa Bashe
Content Producer: Michael Giacobbe
Design Coordinator: Mary Siener
Vice President of Sales and Marketing: David Gesell
Vice President, Director of Marketing: Brad Parkins
Director, Digital Studio: Amy Peltier
Digital Project Manager: Ellen Viganola
Full-Service Project Management and Composition: Pearson CSC
Full-Service Project Manager: Pearson CSC, Dan Knott
Manufacturing Buyer: Maura Zaldivar-Garcia, LSC Communications, Inc.
Cover Designer: Pearson CSC

Copyright © 2020 by Pearson. All rights reserved. Manufactured in the United States of America. This publication is protected by Copyright, and permission should be obtained from the publisher prior to any prohibited reproduction, storage in a retrieval system, or transmission in any form or by any means, electronic, mechanical, photocopying, recording, or likewise. For information regarding permissions, request forms and the appropriate contacts within the Pearson Education Global Rights & Permissions Department, please visit www.pearsoned.com/permissions/

Pearson® is a registered trademark of Pearson plc

Notice: Care has been taken to confirm the accuracy of information presented in this book. The authors, editors, and the publisher, however, cannot accept any responsibility for errors or omissions or for consequences from application of the information in this book and make no warranty, express or implied, with respect to its contents.

Library of Congress Cataloging-in-Publication Data

Names: McKenzie, Shirlyn B., author. | Landis-Piwowar, Kristin, author. | Williams, Joanne Lynne, 1949- author.

Title: Clinical laboratory hematology / Shirlyn B. McKenzie, Kristin Landis-Piwowar, J. Lynne Williams.

Other titles: Pearson clinical laboratory science series.

Description: Fourth edition. | Hoboken : Pearson, [2020] | Series: Pearson's clinical laboratory science series | Includes bibliographical references and index.

Identifiers: LCCN 2019010608 | ISBN 9780134709390 | ISBN 013470939X

Subjects: | MESH: Clinical Laboratory Techniques | Hematology—methods | Hematologic Diseases—diagnosis | Hematopoietic System—physiology

Classification: LCC RB45 | NLM WH 25 | DDC 616.1/5075—dc23 LC record available at <https://lccn.loc.gov/2019010608>



ISBN-13: 978-0-134-70939-0

ISBN-10: 0-134-70939-X

To my family, the wind beneath my wings, Gary, Scott, Shawn, Belynda, and Dora; my special grandchildren Lauren, Kristen, Weston, Waylon, and Wyatt; to the memory of my parents, George and Helen Olson.

—Shirlyn B. McKenzie

To Theron and Kaia, you sustain my every breath and to Todd, you are my rock.

—Kristin R. Landis-Piwowar

For my mother, Mary Williams, who gave her children roots as well as wings; for Lee, Laurie, Roger, and Richard, who sustain my roots; for Dulaney, Corie, Chris, Ava, and Holden, whom I love as my own; and to the memory of my father, David Williams.

—J. Lynne Williams

This page intentionally left blank

Contents

Foreword	xvii	Development of Hematopoiesis	30
Preface	xviii	Hematopoietic Tissue	30
Section One			
Introduction to Hematology	1	Bone Marrow	30
1 Introduction	2	Thymus	34
Overview	3	Spleen	35
Introduction	3	Lymph Nodes	38
Composition of Blood	4	Summary • Review Questions • References	
Reference Intervals for Blood Cell Concentration	4	4 Hematopoiesis	42
Hemostasis	5	Overview	43
Blood Component Therapy	5	Introduction	43
Investigation of a Hematologic Problem	6	Hematopoiesis	44
The Value of Laboratory Testing	6	Hematopoietic Precursor Cells	44
Summary • Review Questions • References		Cytokines and the Control of Hematopoiesis	52
2 Cellular Homeostasis	9	Cytokine Receptors, Signaling Pathways, and Transcription Factors	57
Overview	10	Hematopoietic Microenvironment	59
Introduction	11	Components of the Hematopoietic Microenvironment	61
Review of Cell Structure	11	Hematopoietic Microenvironment Niches	61
Cell Membrane	11	Summary • Review Questions • References	
Cytoplasm	12	5 The Erythrocyte	66
Nucleus	13	Overview	67
Review of the Flow of Genetic Information	13	Introduction	68
DNA Replication	13	Erythropoiesis and Red Blood Cell Maturation	68
Transcription	14	Erythroid Progenitor Cells	68
Translation	14	Erythroid-Maturing Cells	68
Protein Degradation	15	Characteristics of Cell Maturation	69
Tissue Homeostasis: Proliferation, Differentiation, and Apoptosis	15	Erythroblastic Islands	72
Proliferation: The Cell Cycle	16	Erythrocyte Membrane	72
Differentiation	19	Membrane Composition	72
Apoptosis	20	Lipid Composition	73
Abnormal Tissue Homeostasis and Cancer	23	Protein Composition	74
Summary • Review Questions • References		Membrane Permeability	76
Section Two			
The Hematopoietic System	27	Erythrocyte Metabolism	77
3 Structure and Function of Hematopoietic Organs	28	Glycolytic Pathway	77
Overview	29	Hexose Monophosphate (HMP) Shunt	77
Introduction	29	Methemoglobin Reductase Pathway	78
		Rapoport-Luebering Shunt	78
		Erythrocyte Kinetics	80
		Erythrocyte Concentration	80
		Regulation of Erythrocyte Production	80
		Erythrocyte Destruction	82
		Summary • Review Questions • References	

6 Hemoglobin	87	8 Lymphocytes	138
Overview	89	Overview	140
Introduction	89	Introduction	140
Hemoglobin Structure	89	Lymphopoiesis	140
Hemoglobin Synthesis	90	Ontogeny of Lymphopoiesis	140
Heme	90	Transcriptional Regulation of Lymphopoiesis	141
Globin Chain Synthesis	91	Cytokines in Lymphopoiesis	141
Regulation of Hemoglobin Synthesis	94	Antigen-Dependent and -Independent Lymphopoiesis	141
Ontogeny of Hemoglobin	95	Mature Lymphocytes	142
Embryonic Hemoglobins	95	Lineage Differentiation	142
Fetal Hemoglobin	95	B Lymphocytes	143
Adult Hemoglobins	95	T Lymphocytes	147
Glycosylated Hemoglobin	96	Natural Killer Cells	150
Hemoglobin Function	96	Natural Killer T (NKT) Cells	150
Oxygen Transport	96	Lymphocyte Identification and Morphology	151
Carbon Dioxide Transport	100	Morphologic Classification of Immature Lymphocytes	151
Nitric Oxide and Hemoglobin	101	Morphology of Activated Lymphocytes	153
Artificial Oxygen Carriers	101	Lymphocyte Distribution, Concentration, and Kinetics	154
Hemoglobin Catabolism	102	Lymphocyte Function	154
Extravascular Destruction	102	B Lymphocytes (Humoral Immunity)	155
Intravascular Destruction	103	T Lymphocytes (Cell-Mediated Immunity)	156
Acquired Nonfunctional Hemoglobins	104	Natural Killer Cells	157
Methemoglobin	104	Adhesion Molecules of the Adaptive Immune Response	158
Sulfhemoglobin	105	Aging and Lymphocyte Function	159
Carboxyhemoglobin	106	Lymphocyte Metabolism	159
Summary • Review Questions • References		Summary • Review Questions • References	
7 Granulocytes and Monocytes	110	9 The Platelet	163
Overview	112	Overview	164
Introduction	112	Introduction	164
Granulopoiesis and Monocytopoiesis	112	Megakaryocytes	165
Leukocyte Concentration in the Peripheral Blood	113	Megakaryopoiesis	165
Leukocyte Surface Markers	114	Thrombopoiesis	169
Leukocyte Function	114	Peripheral Blood Platelets	169
Neutrophils	115	Platelet Morphology	169
Differentiation, Maturation, and Morphology	115	Quantitative Platelet Evaluation	170
Distribution, Concentration, and Kinetics	119	Platelet Function	170
Function	120	Summary • Review Questions • References	
Eosinophils	126	10 The Complete Blood Count and Peripheral Blood Smear Evaluation	174
Differentiation, Maturation, and Morphology	126	Overview	176
Distribution, Concentration, and Kinetics	127	Introduction	176
Function	128	Pre-Examination Phase of the CBC	177
Basophils	128	Examination Phase of the CBC	177
Differentiation, Maturation, and Morphology	129	Automated Results	177
Distribution, Concentration, and Kinetics	129	The Peripheral Blood Smear	181
Function	129	Clinical Laboratory Professional's Review of CBC Data	193
Monocytes	130		
Differentiation, Maturation, and Morphology	130		
Distribution, Concentration, and Kinetics	132		
Function	132		
Summary • Review Questions • References			

Post-Examination Phase of the CBC	194	Laboratory Evaluation	242
Physiologic Variation in Hematologic Parameters	194	Therapy	245
CBC Variations in Newborns and Children	194	Anemia of Chronic Disease	245
CBC Variations Between Ethnic Groups and Sexes, in Elderly People, and by Geographic Location	194	Etiology	245
Summary • Review Questions • References		Pathophysiology	245
		Clinical Presentation	246
		Laboratory Evaluation	246
		Therapy	247
		Iron Refractory Iron-Deficiency Anemia (Irida)	247
		Pathophysiology	247
		Clinical Presentation	247
		Laboratory Evaluation	247
		Therapy	248
		Functional Iron Deficiency (Fid)	248
		Etiology	248
		Laboratory Evaluation	248
		Therapy	248
		Anemias Associated with Abnormal Heme Synthesis	248
		Sideroblastic Anemias	248
		Therapy	253
		Hemochromatosis	253
		Hereditary Hemochromatosis	253
		Secondary Hemochromatosis	255
		Treatment	255
		Porphyrias	255
		Etiology	255
		Pathophysiology	256
		Clinical Presentation	258
		Laboratory Evaluation	258
		Prognosis and Therapy	258
		Summary • Review Questions • References	
		13 Hemoglobinopathies: Qualitative Defects	265
		Overview	267
		Introduction	267
		Structural Hemoglobin Variants	268
		Identification of Hemoglobin Variants	268
		Methods of Analysis	269
		Nomenclature	270
		Pathophysiology	271
		Sickle Cell Anemia	271
		Pathophysiology	271
		Clinical Presentation	273
		Laboratory Evaluation	276
		Therapy	277
		Sickle Cell Trait	278
		Other Sickling Disorders	278
		Hemoglobin C Disease	279
		Hemoglobin S/C Disease	279
		Hemoglobin D	280
		Hemoglobin E	281

Section Three

The Anemias 199

11 Introduction to Anemia 200

Overview	202
Introduction	202
How Anemia Develops	202
Interpretation of Abnormal Hemoglobin Concentrations	203
Adaptations to Anemia	203
Increase in Oxygenated Blood Flow	204
Increase in Oxygen Utilization by Tissue	204
Diagnosis of Anemia	204
History	204
Clinical Presentation	204
Laboratory Evaluation	206
Classification of Anemias	211
Morphologic Classification	211
Functional Classification	213
Classification Using the Red Cell Distribution Width	218
Laboratory Testing Schemas for Anemia Diagnosis	218
Summary • Review Questions • References	

12 Anemias of Disordered Regulation of Iron Metabolism and Heme Synthesis 224

Overview	226
Introduction	227
Iron Metabolism	227
Distribution	228
Absorption	228
Transport	230
Storage	232
Physiological Regulation of Iron Balance	233
Iron Requirements	238
Laboratory Assessment of Iron	238
Iron Studies	238
Iron-Deficiency Anemia	240
Historical Aspects	240
Etiology	240
Pathophysiology	241
Clinical Presentation	241

Unstable Hemoglobin Variants	281	Megaloblastic Anemia	323
Pathophysiology	281	Clinical Presentation	323
Clinical Presentation	282	Laboratory Evaluation	324
Laboratory Evaluation	282	Folate	327
Therapy	283	Cobalamin (Vitamin B ₁₂)	331
Hemoglobin Variants With Altered Oxygen Affinity	283	Other Megaloblastic Anemias	338
Hemoglobin Variants with Increased Oxygen Affinity	283	Macrocytic Anemia Without Megaloblastosis	340
Hemoglobin Variants with Decreased Oxygen Affinity	283	Alcoholism	340
Methemoglobinemias	284	Liver Disease	341
Summary • Review Questions • References		Stimulated Erythropoiesis	342
		Hypothyroidism	342
		Summary • Review Questions • References	
14 Thalassemia	289	16 Hypoproliferative Anemias	346
Overview	291	Overview	348
Introduction	291	Introduction	348
Thalassemia versus Hemoglobinopathy	292	Aplastic Anemia	348
Types of Thalassemia	292	Epidemiology	348
Genetic Defects in Thalassemia	293	Pathophysiology	348
Pathophysiology	293	Classification and Etiology	349
Clinical Presentation	294	Clinical Presentation	352
Laboratory Evaluation	295	Laboratory Evaluation	353
Treatment	295	Prognosis and Therapy	354
α -Thalassemia	296	Differentiation of Aplastic Anemia from other Causes of Pancytopenia	355
General Considerations	296	Pure Red Cell Aplasia	356
α -Thalassemia Major (α^0/α^0 or α -thal-1/ α -thal-1); Hydrops Fetalis	298	Acute Acquired Pure Red Cell Aplasia	356
Hemoglobin H Disease (α^0/α^+ or α -thal-1/ α -thal-2)	298	Chronic Acquired Pure Red Cell Aplasia	357
α -Thalassemia Minor (α^+/α^+ or α -thal-2/ α -thal-2; α^0/α or α -thal-1/normal)	300	Diamond-Blackfan Syndrome	357
Silent Carrier (α^+/α or α -thal-2/normal)	301	Other Hypoproliferative Anemias	358
β -Thalassemia	301	Renal Disease	358
General Considerations	301	Endocrine Abnormalities	359
β -Thalassemia Major (β^0/β^0 , β^0/β^+ , β^+/β^+)	303	Summary • Review Questions • References	
β -Thalassemia Minor (β^0/β or β^+/β)	306	17 Hemolytic Anemia: Membrane Defects	364
β -Thalassemia Intermedia (β^+/β^+ , β^0/β^+ , β^0/β)	307	Overview	366
β -Thalassemia Minima (β^{SC}/β)	307	Introduction	366
Other Thalassemias and Thalassemia-Like Conditions	308	Skeletal Protein Abnormalities	366
$\delta\beta$ Thalassemia	308	Vertical Interactions	366
$\gamma\delta\beta$ Thalassemia	308	Horizontal Interactions	366
Hemoglobin Constant Spring	308	Lipid Composition Abnormalities	366
Hereditary Persistence of Fetal Hemoglobin (HPFH)	309	Hereditary Spherocytosis	367
Hemoglobin Lepore	310	Pathophysiology	368
Combination Disorders	311	Clinical Presentation	369
Differential Diagnosis of Thalassemia	313	Laboratory Evaluation	369
Summary • Review Questions • References		Identification of Deficient/Defective Membrane Protein	371
		Therapy	371
15 Megaloblastic and Nonmegaloblastic Macrocytic Anemias	319		
Overview	321		
Introduction	321		

Hereditary Elliptocytosis	371	Clinical Presentation	393
Pathophysiology	371	Laboratory Evaluation	394
Clinical Presentation	372	Therapy	394
Laboratory Evaluation	372	Other Enzyme Deficiencies in the Glycolytic Pathway	394
Therapy	373	Abnormal Erythrocyte Nucleotide Metabolism	395
Hereditary Pyropoikilocytosis (HPP)	373	Summary • Review Questions • References	
Pathophysiology	373	19 Hemolytic Anemia: Immune Anemias	399
Clinical Presentation	373	Overview	401
Laboratory Evaluation	374	Introduction	401
Therapy	374	Classification Of Immune Hemolytic Anemias	401
Hereditary Stomatocytosis Syndromes	374	Sites And Factors That Affect Hemolysis	403
Pathophysiology	375	Mechanisms Of Hemolysis	404
Laboratory Evaluation	375	IgG-Mediated Hemolysis	404
Therapy	375	Complement-Mediated Hemolysis	404
Abnormal Membrane Lipid Composition:		IgM-Mediated Hemolysis	405
Acanthocytosis	375	Laboratory Identification of Sensitized Red Cells	405
Spur Cell Anemia	376	Direct Antiglobulin Test	406
Abetalipoproteinemia (Hereditary Acanthocytosis)	376	Indirect Antiglobulin Test	406
Lecithin-Cholesterol Acyl Transferase (LCAT) Deficiency	377	Negative DAT in AIHA	407
Rare Forms	377	Positive DAT in Normal Individuals	407
Paroxysmal Nocturnal Hemoglobinuria (PNH)	377	Autoimmune Hemolytic Anemias (AIHA)	407
Pathophysiology	377	Warm Autoimmune Hemolytic Anemia	408
Clinical Presentation	378	Laboratory Evaluation	409
Laboratory Evaluation	378	Cold Autoimmune Hemolytic Anemia	411
Therapy	379	Paroxysmal Cold Hemoglobinuria	414
Summary • Review Questions • References		Mixed-Type AIHA	415
18 Hemolytic Anemia: Enzyme Deficiencies	383	Drug-Induced Hemolytic Anemias	415
Overview	385	Alloimmune Hemolytic Anemia	417
Introduction	385	Hemolytic Transfusion Reactions	418
Hexose Monophosphate Shunt	385	Hemolytic Disease of the Fetus and Newborn (HDFN)	419
Glycolytic Pathway	385	Summary • Review Questions • References	
Clinical and Laboratory Evaluation in Erythrocyte Enzyme Deficiencies	386	20 Hemolytic Anemia: Nonimmune Defects	429
Diagnosis	387	Overview	431
Glucose-6-Phosphate Dehydrogenase Deficiency	387	Introduction	431
Etiology	387	Hemolytic Anemia Caused by Physical Injury to the Erythrocyte	431
Pathophysiology	387	Thrombotic Microangiopathic Anemia (TMA)	431
G6PD Variants	389	Other Erythrocyte Physical Trauma Resulting in Hemolytic Anemia	439
Females with G6PD Deficiency	389	Hemolytic Anemias Caused by Antagonists in the Blood	440
Clinical Presentation	390	Infectious Agents	440
Laboratory Evaluation	391	Animal Venoms	442
Differential Diagnosis	392	Chemicals and Drugs	442
Therapy	392	Summary • Review Questions • References	
Other Defects and Deficiencies of the HMP Shunt and GSH Metabolism	393		
Pyruvate Kinase (Pk) Deficiency	393		
Etiology	393		
Pathophysiology	393		

Section Four

Nonmalignant Disorders of Leukocytes 449

21 Nonmalignant Disorders of Leukocytes: Granulocytes and Monocytes 450

Overview	452
Introduction	452
Neutrophil Disorders	453
Quantitative Disorders	453
Qualitative or Morphologic Abnormalities	458
Eosinophil Disorders	464
Nonclonal (Reactive) Hypereosinophilia	464
Clonal (Neoplastic) Hypereosinophilia	465
Idiopathic Hypereosinophilia	465
Basophil and Mast Cell Disorders	466
Monocyte/Macrophage Disorders	466
Quantitative Disorders	466
Qualitative Disorders	467
Summary • Review Questions • References	

22 Nonmalignant Lymphocyte Disorders 473

Overview	475
Introduction	475
Lymphocytosis	475
Infectious Mononucleosis	476
Toxoplasmosis	479
Cytomegalovirus	479
<i>Bordetella Pertussis</i>	480
Reactive Lymphocytosis	480
Plasmacytosis	481
Persistent Polyclonal B-Cell Lymphocytosis	481
Lymphocytopenia	482
Lymphocyte Sequestration and Destruction	482
Immune Deficiency Disorders	483
Summary • Review Questions • References	

Section Five

Neoplastic Hematologic Disorders 495

23 Introduction to Hematopoietic Neoplasms 496

Overview	498
Introduction	498

Pathophysiology	499
Cancer Stem Cells	500
Molecular Basis of Cancer	500
Leukemogenesis	504
Epidemiology	505
Clinical Presentation	505
Laboratory Evaluation	506
Hematopoietic Neoplasm Classification	506
Laboratory Procedures for Diagnosing and Classifying Neoplasms	507
Cytochemical Analysis	508
Immunologic Analysis	508
Genetic Analysis	509
Prognosis and Treatment of Neoplastic Disorders	509
Prognosis	509
Treatment	510
Summary • Review Questions • References	

24 Myeloproliferative Neoplasms 517

Overview	519
Introduction	519
Classification	520
Pathophysiology	521
General Features	521
Chronic Myeloid Leukemia (CML)	522
Etiology and Pathophysiology	523
Clinical Presentation	525
Laboratory Evaluation	525
Terminal Phase	527
Therapy	528
Differential Diagnosis	529
Chronic Neutrophilic Leukemia (CNL)	530
Etiology and Pathophysiology	530
Clinical Presentation	530
Laboratory Evaluation	530
Therapy	531
Differential Diagnosis	531
Essential Thrombocythemia (ET)	531
Etiology and Pathophysiology	531
Clinical Presentation	532
Laboratory Evaluation	532
Prognosis and Therapy	534
Differential Diagnosis	534
Polycythemia Vera (PV)	535
Classification	535
Etiology and Pathophysiology	535
Clinical Presentation	537
Laboratory Evaluation	537
Prognosis and Therapy	538
Differential Diagnosis	539
Relative Polycythemia	539

Primary Myelofibrosis (PMF)	540	Therapy	573
Etiology and Pathophysiology	541	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNS)	574
Clinical Presentation	542	Chronic Myelomonocytic Leukemia (CMML)	574
Laboratory Evaluation	542	Atypical Chronic Myeloid Leukemia (aCML, <i>BCR/ABL1</i> ⁻)	575
Prognosis and Therapy	544	Juvenile Myelomonocytic Leukemia	575
Differential Diagnosis	544	MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)	576
Myeloproliferative Neoplasm, Unclassifiable (MPN, U)	545	Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U)	576
Clonal Hypereosinophilia	545	Summary • Review Questions • References	
Myeloid and Lymphoid Neoplasms Associated with Eosinophilia and <i>PDGFRA</i> , <i>PDGFRB</i> , or <i>FGFR1</i> Mutations	546	26 Acute Myeloid Leukemias	583
Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS)	547	Overview	585
Idiopathic Hypereosinophilic Syndrome (I-HES)	548	Introduction	585
Mast Cell Disease (Mastocytosis)	548	Etiology And Pathophysiology	585
Summary • Review Questions • References		Laboratory Evaluation	585
25 Myelodysplastic Syndromes	555	Peripheral Blood	585
Overview	557	Bone Marrow	586
Introduction	557	Other Laboratory Evaluation	587
Pathophysiology	557	Classification	587
Cytogenetics, Epigenetics, and Single Gene Mutations	558	Identification of Cell Lineage	587
Proliferation Abnormalities	560	WHO Classification of AML	591
Incidence	560	Therapy	601
Clinical Presentation	560	Summary • Review Questions • References	
Laboratory Evaluation	560	27 Precursor Lymphoid Neoplasms	606
Peripheral Blood	560	Overview	608
Bone Marrow	563	Introduction	608
Molecular Diagnostics	564	Etiology and Pathophysiology	608
Additional Laboratory Evaluation	565	Clinical Presentation	608
Blast and Precursor Cell Classification	565	Laboratory Evaluation	609
Myeloblasts	565	Peripheral Blood	609
Promyelocytes	566	Bone Marrow	610
Ring Sideroblasts	566	Tissue Involvement	610
Immunological Identification of Blasts	567	Other Laboratory Evaluation	611
Classification	567	Identification of Cell Lineage	611
Description of MDS Subgroups	568	Morphology and Cytochemistry	611
MDS with Single Lineage Dysplasia (MDS-SLD)	568	Terminal Deoxynucleotidyl Transferase (TdT)	611
MDS with Ring Sideroblasts (MDS-RS)	569	Immunophenotyping	611
MDS with Multilineage Dysplasia (MDS-MLD)	569	Cytogenetic Analysis	612
MDS with Excess Blasts (MDS-EB)	569	Molecular Analysis	612
MDS with Isolated del(5q)	570	WHO Classification	612
MDS, Unclassifiable (MDS-U)	570	B Lymphoblastic Leukemia/Lymphoma	612
Refractory Cytopenia of Childhood	570	T Lymphoblastic Leukemia/Lymphoma	615
Variables of MDS Subgroups	571	Acute Leukemias of Ambiguous Lineage	616
Hypoplastic MDS	571	Natural Killer Cell Lymphoblastic Leukemia/Lymphoma	617
MDS with Fibrosis	571	Therapy	617
Therapy-Related Myelodysplasia	571	Summary • Review Questions • References	
Differential Diagnosis	571		
Prognosis	572		

28 Mature Lymphoid Neoplasms	622	Cryopreservation and Storage of Hematopoietic Stem Cells	652
Overview	624	Infusion of Hematopoietic Stem Cells	652
Introduction	624	Quantitation of Hematopoietic Stem Cells	652
Etiology and Pathophysiology	624	Determination of Mononuclear Cell Count	652
Acquired Genetic Factors	624	CD34 Enumeration by Flow Cytometry	652
Inherited Genetic Factors	624	Cell Culture for Colony Forming Units	653
Environmental Factors	625	Collection Target for Stem Cells	653
Diagnosis and WHO Classification	625	Hematopoietic Engraftment	654
Laboratory Evaluation	625	Evidence of Initial Engraftment	654
Prognosis	625	Evidence of Long-Term Engraftment	654
Therapy	625	Role of the Clinical Laboratory Professional in Stem Cell Transplantation	654
Staging	626	Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect	655
Mature B Cell Neoplasms	626	Complications Associated with Stem Cell Transplantation	656
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	626	Early Complications	656
B Cell Prolymphocytic Leukemia	628	Late Complications	657
Hairy Cell Leukemia	628	Increased Availability and Success of Stem Cell Transplantation	657
Follicular Lymphoma	629	Gene Therapy	657
Mantle Cell Lymphoma (MCL)	630	Summary • Review Questions • References	
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	632	Section Six	
Lymphoplasmacytic Lymphoma	632	Body Fluids	663
Diffuse Large B Cell Lymphoma	633	30 Morphologic Analysis of Body Fluids in the Hematology Laboratory	664
Burkitt Lymphoma	634	Overview	666
Plasma Cell Neoplasms	634	Introduction	666
Mature T and NK Cell Neoplasms	636	Types of Body Fluids	666
Nodal T and NK Cell Lymphomas	637	Serous Fluids	667
Extranodal T and NK Cell Lymphomas	638	Cerebrospinal Fluid	668
Leukemic T and NK Cell Lymphomas	639	Synovial Fluid	670
Hodgkin Lymphoma (HL)	640	Bronchoalveolar Lavage (BAL)	670
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)	640	Hematologic Analysis of Body Fluids	670
Classical Hodgkin Lymphoma (CHL)	640	Specimen Collection and Handling	670
Summary • Review Questions • References		Physical Characteristics	671
29 Hematopoietic Stem Cell Transplantation	645	Cell Counting	672
Overview	647	Nucleated Cell Differential	675
Introduction	647	Analysis of Other Fluids	693
Origin and Differentiation of Hematopoietic Stem Cells	647	BAL Fluid	693
Sources of Hematopoietic Stem Cells and Types of Stem Cell Transplants	648	Amniotic Fluid Lamellar Body Counts	693
Allogeneic Stem Cell Transplantation	648	Semen Analysis	695
Autologous Stem Cell Transplantation	649	Summary • Review Questions • References	
Umbilical Cord Blood Stem Cell Transplantation	650	Section Seven	
Collection and Processing of Hematopoietic Stem Cells	650	Hemostasis	703
Bone Marrow	651	31 Primary Hemostasis	704
Peripheral Blood	651		
Umbilical Cord Blood	651		
Purging	651		

Overview	706	Clinical Manifestations of Secondary Hemostasis	
Introduction	706	Bleeding Disorders	770
Role of the Vascular System	707	Nonspecific Bleeding	770
Structure of Blood Vessels	707	Evaluation of a Patient with Abnormal Bleeding	770
Functions of Blood Vessels in Hemostasis	709	Laboratory Evaluation of Abnormal Bleeding	771
Functions of Endothelial Cells	709	Hereditary Vascular System Disorders	773
Platelets in Hemostasis	711	Acquired Vascular System Disorders	773
Platelet Structure	712	Purpura Resulting from Decreased Connective Tissue	773
Platelet Functions	718	Purpura Associated with Dysproteinemias	773
Physiologic Controls of Platelet Activation and Aggregation	726	Purpura Resulting from Vasculitis	774
Summary • Review Questions • References		Miscellaneous Causes of Purpura	774
32 Secondary Hemostasis and Fibrinolysis	731	Quantitative Platelet Disorders	775
Overview	733	Thrombocytopenia	775
Introduction	733	Thrombocytosis	785
The Coagulation Mechanism	734	Artifacts in the Quantitative Measurement of Platelets	786
Procoagulant Factors	734	Qualitative (Functional) Platelet Disorders	787
Properties of the Blood Coagulation Factors	735	Hereditary Disorders of Platelet Function	787
Mechanism of Action	737	Acquired Disorders of Platelet Function	792
Vitamin K–Dependent Coagulation Proteins	737	Summary • Review Questions • References	
Structure of the Blood Coagulation Proteins	738	34 Disorders of Secondary Hemostasis	798
Coagulation Cascade	738	Overview	800
Complex Formation on Phospholipid Surfaces	738	Introduction	800
The Intrinsic Pathway	738	Bleeding Characteristics	800
The Extrinsic Pathway	744	Laboratory Evaluation	801
The Common Pathway	745	Hereditary Disorders of Secondary Hemostasis	802
Fibrinolytic System	749	Autosomal Dominant Inheritance – von Willebrand Disease	802
Components of the Fibrinolytic System	749	X-Linked Recessive Disorders	807
Plasminogen (PLG) and Plasmin (PLN)	750	Autosomal Recessive Disorders	812
Activators of Fibrinolysis	751	Acquired Disorders of Hemostasis Associated with Bleeding	817
Fibrin Degradation	752	Common Bleeding Disorders in the Neonate	820
Inhibitors of Fibrinolysis	753	Summary • Review Questions • References	
Control of Hemostasis	755	35 Thrombophilia	826
Blood Flow	755	Overview	828
Liver Clearance	755	Introduction	828
Positive Feedback Amplification	755	Thrombus Formation	829
Negative Feedback Inhibition	755	Arterial Thrombi	829
Biochemical Inhibitors	755	Venous Thrombi	830
Physiologic Hemostasis	760	Microparticles in Arterial and Venous Thrombosis	831
The Tissue Factor Pathway	760	Thrombophilia	832
Basal Coagulation	761	Hereditary Thrombophilia	833
Hemostasis in the Newborn	762	Other Potential Genetic Risk Factors	839
Summary • Review Questions • References		Acquired Thrombohemorrhagic Conditions	841
33 Disorders of Primary Hemostasis	767	Laboratory Testing in Patients with Suspected Thrombosis	853
Overview	769	Anticoagulant Therapy	854
Introduction	769	Heparin	855
Diagnosis of Bleeding Disorders	769	Oral Anticoagulants	856
Clinical Manifestations of Primary Hemostasis Bleeding Disorders	770		

New Oral Anticoagulants (NOAC)/Direct Oral Anticoagulants (DOAC)	857
Thrombolytic Therapy	857
Antiplatelet Therapy	858
Summary • Review Questions • References	

36 Hemostasis: Laboratory Testing and Instrumentation 866

Overview	868
Introduction	869
Specimen Collection and Processing	869
Specimen Collection	869
Specimen Processing	871
Laboratory Investigation of Primary Hemostasis	871
Bleeding Time	871
Platelet Function Analyzers	872
Laboratory Investigation of Secondary Hemostasis	875
Screening Tests	875
Tests to Identify a Specific Factor Deficiency	877
Identification of Inhibitors	882
Laboratory Investigation of the Fibrinolytic System	884
D-Dimer	884
Fibrin Degradation Products	885
Euglobulin Clot Lysis	885
α_2 -Antiplasmin Activity	885
Laboratory Investigation of Hemostasis (Primary, Secondary, or Fibrinolytic Pathway) Using Global Assays	886
Thromboelastography (TEG)	886
ROTEM [®] (TEM)	886
Calibrated Automated Thrombogram (CAT)	886
Laboratory Investigation of Hereditary and Acquired Thrombophilias (Hypercoagulable States)	887
Antithrombin (AT)	887
Protein C	888
Protein S	889
Activated Protein C Resistance (APCR)	889
Prothrombin G20210A	889
Additional Testing for Thrombosis	890
Molecular Markers of Hemostatic Activation	891
Laboratory Evaluation: Assessment for Pharmaceutical Intervention of Hemostasis	891
Oral Vitamin K Antagonist Therapy and the Prothrombin Time-INR Value	891
Direct Oral Anticoagulants (DOACs)	892
Non-Parenteral Anticoagulation	893
Direct Thrombin Inhibitor (DTI) Therapy	894
Monitoring	894
Hemostasis Instrumentation	895
Evolution of Hemostasis Testing	895
Automated Hemostasis Analyzer Methodologies	895
Point-of-Care Hemostasis Instrumentation	897
Summary • Review Questions • References	

Section Eight

Hematology Procedures 905

37 Hematology Procedures 906

Overview	909
Introduction	909
Laboratory Testing Regulations	909
Specimen Collection: Phlebotomy	910
Anticoagulants	910
Equipment	911
Venipuncture	912
Capillary Puncture	913
Phlebotomy Safety	914
Microscopy: The Microscope	914
Bright-Field Microscopy	914
Phase-Contrast Microscopy	915
Koehler Illumination	916
Preventative Maintenance	917
Peripheral Blood Smear Preparation	917
Manual Method	917
Automated Method	918
Peripheral Blood Smear Staining	918
Peripheral Blood Smear Examination	919
Cell Enumeration by Hemacytometer	921
Manual Leukocyte Count	921
Manual Erythrocyte Count	922
Manual Platelet Count	922
Hemoglobin Concentration	922
Hematocrit	923
Erythrocyte Indices	923
Erythrocyte Sedimentation Rate (ESR)	924
Reticulocyte Count	926
Solubility Test for Hemoglobin S	927
Hemoglobin Electrophoresis	928
Quantitation Of Hemoglobin A ₂	929
Acid Elution for Hemoglobin F	929
Quantitation of Hemoglobin F	930
Alkali Denaturation	930
Other Methods	930
Heat Denaturation Test for Unstable Hemoglobin	930
Heinz Body Stain	931
Osmotic Fragility Test	931
Donath-Landsteiner Test for Paroxysmal Cold Hemoglobinuria (PCH)	931
Erythropoietin	933
Soluble Transferrin Receptor	933
Cytochemical Stains	934
Myeloperoxidase	934
Sudan Black B	934
Chloroacetate Esterase	935

α -Naphthyl Esterase (Nonspecific Esterase)	936	40 Flow Cytometry	993
Periodic Acid-Schiff	936	Overview	995
Leukocyte Alkaline Phosphatase	937	Introduction	995
Acid Phosphatase and Tartrate-Resistant Acid Phosphatase (TRAP)	937	Principles of Flow Cytometry	995
Terminal Deoxynucleotidyl Transferase	938	Isolation of Single Particles	995
Toluidine Blue	938	Light Scattering	996
Reticulin Stain and Masson's Trichrome Stain	939	Detection of Fluorochromes	997
Summary • Review Questions • References		Data Analysis	998
38 Bone Marrow Examination	945	Immunophenotyping by Flow Cytometry	998
Overview	947	Specimen Requirements and Preparation for Immunophenotyping	1000
Introduction	947	Isolation of Cells by Gating	1000
Indications for Bone Marrow Evaluation	947	Fluorescence Activated Cell Sorting (FACS)	1000
Bone Marrow Procedure	948	Diagnosis and Classification of Mature Lymphoid Neoplasms	1001
Bone Marrow Processing for Examination	949	Diagnosis and Classification of Acute Leukemia	1002
Bone Marrow Aspirate	949	Diagnosis of Myelodysplastic Syndrome (MDS)	1004
Bone Marrow Core Biopsy	949	Detection of Minimal Residual Disease (MRD) by Flow Cytometry	1005
Morphologic Interpretation of Bone Marrow	950	Diagnosis and Surveillance of Immunodeficiency Disorders	1005
Bone Marrow Aspirate	950	Flow Cytometry in Systemic Autoimmune Disease	1006
Bone Marrow Touch Imprints	952	CD34 Enumeration	1007
Bone Marrow Clot and Particle Preparation, Sections, and Core Biopsy	952	Paroxysmal Nocturnal Hemoglobinuria (PNH)	1007
Benign Lymphoid Aggregates versus Malignant Lymphoma	953	Hereditary Spherocytosis (HS)	1008
Bone Marrow Iron Stores	954	DNA Analysis	1008
Special Studies on Bone Marrow	955	Proliferation	1008
Flow Cytometry	955	Ploidy	1008
Cytogenetics	955	Clinical Applications of DNA Analysis	1009
Molecular Genetics	955	Summary • Review Questions • References	
Cytochemical Stains	957	41 Chromosome Analysis of Hematopoietic and Lymphoid Disorders	1013
Bone Marrow Report	957	Overview	1015
Summary • Review Questions • References		Introduction	1015
39 Automation in Hematology	961	Chromosome Structure and Morphology	1015
Overview	962	Mitosis	1016
Introduction	962	Cytogenetic Procedures	1017
Automated Blood Cell-Counting Instruments	963	Specimen Preparation	1017
Impedance Instruments	963	Harvest Procedure and Banding	1018
Coulter® LH Series	963	Chromosome Analysis	1019
Beckman-Coulter Unicyel® DxH 800	968	Chromosome Abnormalities	1020
Sysmex XE-Series™	971	Numerical Aberrations	1020
Sysmex XN-Series™	977	Structural Aberrations	1022
Abbott CELL-DYN Sapphire®	980	Polymorphic Variation	1022
Light-Scattering Instruments	984	Cytogenetic Nomenclature	1022
Siemens Healthcare ADVIA 120	984	Cytogenetic Analysis of Hematopoietic and Lymphoid Disorders	1023
Siemens Healthcare ADVIA 2120	987	Processing Specimens	1024
Automated Digital Cell Morphology Instrument	987	Chronic Myelogenous Leukemia	1024
CellaVision® DM96 System	987		
Summary • Review Questions • References			

Myeloproliferative Neoplasms Other Than CML	1026
Acute Myeloid Leukemia	1026
Myelodysplastic Syndromes	1027
Acute Lymphoblastic Leukemia/Lymphoma	1027
Lymphoma and Lymphoproliferative Disorders	1027
Bone Marrow Transplantation	1028
Molecular Cytogenetics	1028
Summary • Review Questions • References	

42 Molecular Analysis of Hematologic Diseases 1033

Overview	1035
Introduction	1035
Overview of Molecular Technologies	1036
Nucleic Acid Extraction	1036
Nucleic Acid Amplification	1036
Hybridization Techniques	1040
Direct DNA Sequence Analysis	1042
Chain Termination Sequencing	1042
Clinical Applications of Molecular Diagnostics in Hematopathology	1043
Erythrocyte Disorders	1045
Leukocyte Disorders	1046
Infectious Diseases	1048
Clinical Applications of Molecular Diagnostics in Hemostasis	1049
CYP2C9	1049
VKORC1	1049
Factor V Leiden (FVL)	1049
Prothrombin G20210A	1049
Hemophilia A	1049
Hemophilia B	1049
Methylenetetrahydrofolate Reductase (<i>MTHFR</i>)	1049
von Willebrand Disease (VWD)	1049
Summary • Review Questions • References	

Section Nine

Quality Assessment 1053

43 Quality Assessment in the Hematology Laboratory 1054

Overview	1056
Test Coding and Reimbursement	1056

Quality Assessment	1056
Basic Components	1056
Proficiency Testing	1060
Competency Testing	1060
Method Evaluation/Instrument Comparison	1061
Reference Interval Determination	1064
Laboratory Safety	1065
Quality Control	1066
Control Materials	1066
Establishing Quality Control (QC) Limits	1066
Interpreting Quality Control Charts	1066
Bull's Testing Algorithm (Moving Averages)	1067
Monitoring Quality Control with Patient Specimens	1068
Individual Quality Control Plan	1068
Review of Patient Results	1069
Hematology	1069
Hemostasis	1073
Summary • Review Questions • References	

Appendices

APPENDIX A	1078
APPENDIX B: Hematopoietic and Lymphoid Neoplasms: Immunophenotypic and Genetic Features	1082
APPENDIX C: 2017 WHO Classification of Hematologic, Lymphopoietic, Histiocytic/Dendritic Neoplasms	1086
APPENDIX D: Hematology Procedures	1089
APPENDIX E: Answers to Review Questions	1104
APPENDIX F: Answers to Checkpoints	1111
APPENDIX G: Answers to Case Study Questions	1150
Glossary	1179
Index	1209

Foreword

Clinical Laboratory Hematology is part of Pearson's Clinical Laboratory Science (CLS) series of products, which is designed to balance theory and practical applications in a way that is engaging and useful to students. The authors of and contributors to *Clinical Laboratory Hematology* present highly detailed technical information and real-life case studies that will help learners envision themselves as members of the health care team, providing the laboratory services specific to hematology that assist in patient care. The mixture of theoretical and practical information relating to hematology provided in this text allows learners to analyze and synthesize this information and, ultimately, to answer questions and solve problems and cases. Additional instructional resources are available at www.pearson.com

Elizabeth A. Gockel-Blessing, PhD, MT(ASCP), CLS(NCA)
Clinical Laboratory Science Series Editor
Pearson Health Science
Vice Chair & Associate Professor
Department of Clinical Laboratory Science
Doisy College of Health Sciences
Saint Louis University

Preface

Revel™ for *Clinical Laboratory Hematology* takes on a new face as a digital textbook. Revel is Pearson's newest way of delivering our respected content. Fully digital and highly engaging, Revel offers an immersive learning experience designed for the way today's students read, think, and learn. Enlivening course content with media interactives and assessments, Revel empowers educators to increase engagement with the course, and to better connect with students. To our knowledge this is the first book written for medical laboratory technician (MLT) and medical laboratory science (MLS) students in this format. Pearson performed in-depth analysis to determine the learning preferences of our students and teaching methods of instructors. The results indicated that many students prefer to read and study using digital resources. Furthermore, on-line instruction is now commonplace. Based on this knowledge, the decision was made to update to the fourth edition using the Revel platform. The focus of the book remains the same; it is a comprehensive resource that MLT and MLS students can use in all their hematology courses. Laboratory practitioners will find the book a welcome resource to help them keep up with advances in the field. Although the book is primarily written for clinical laboratory students and practitioners, it also is suited for use by students and practitioners in other health care professions including pathology, medicine, physician assistant, and nursing. Great effort has been put in by our authors to ensure this edition is thoroughly updated to include the latest in advances in laboratory medicine. Each chapter has a similar format that makes it easy for readers to find information on each topic. The digital format makes it convenient to instantly find word definitions, cell images, and other information as needed. An image atlas, test bank, powerpoint presentation and instructor's manual are available for instructors who adopt the book for their classes. In summary, the book is not just a book but a package of learning tools.

You will note that we have added a new editor, Dr. Kristin Piwovar-Landis. Kristin was a consulting editor on the previous edition. Based on her outstanding writing and editing skills as well as thorough knowledge of hematology with a focus on hematopoietic genetics, she was invited to serve as an editor in this edition with Dr. McKenzie as her mentor. The ultimate goal is for Kristin to replace Dr. McKenzie who wants to retire from the responsibilities of primary editor in future editions. It has been a pleasure to mentor her through the book writing process. Dr. Lynne Williams continues as an editor in this edition. Lynne's in-depth knowledge in hemostasis as well as cellular biology shines through in the chapters she authors.

Organization

We believe that students must have a thorough knowledge of normal hematopoiesis and cell processes to understand the pathophysiology of hematologic/hemostatic diseases, evaluate and correlate laboratory test results, and ensure the appropriate utilization of the laboratory in diagnosis and patient follow-up. Thus, this book is organized so that the first nine chapters give the students a comprehensive base of knowledge about blood cell proliferation, maturation, and differentiation and the processes that control hematopoiesis. Section One (Chapters 1–2) includes an introduction to hematology and hematopoiesis, including cell morphology and the cell cycle and its regulation. This introduction includes a description of cellular processes at the molecular level, which could be new material for some students and a basic review for others. The reader might want to review these chapters before beginning a study of neoplastic disorders (Chapters 23–28). Section Two (Chapters 3–10) includes chapters on normal hematopoiesis, including a description of the structure and function of hematopoietic tissue and organs, erythropoiesis, leukopoiesis, thrombopoiesis, and hemoglobin. Hemoglobin synthesis, function, and breakdown are discussed in Chapter 6. The chapter on leukocytes is divided into two separate chapters: granulocytes/monocytes (Chapter 7) and lymphocytes (Chapter 8). An introductory chapter on platelets (Chapter 9) completes the discussion of normal blood cells. Details of platelet function and physiology are found in Section Seven, Chapter 31. Rounding out this section, "The Complete Blood Count and Peripheral Blood Smear Examination" (Chapter 10) describes the information that can be gained about blood cells from these frequently ordered laboratory tests. Most of the remaining chapters refer to the tests that are described in this chapter.

The next three sections include discussions of hematologic disorders. Section Three (Chapters 11–20) begins with an introduction to anemia (Chapter 11). We combined the introduction to anemia and the introduction to hemolytic anemia into one chapter because many anemias have a hemolytic component. This chapter is followed by chapters on the various anemias. Each anemia is discussed in the following manner: introduction, etiology, pathophysiology, clinical presentation, laboratory presentation, and therapy. This format helps readers understand what laboratory tests can help in diagnosis and how to interpret the results of these tests. Section Four (Chapters 21 and 22) covers the nonmalignant disorders of leukocytes. Section Five (Chapters 23–29) is a study of hematopoietic neoplasms. This section begins with

an overview of these disorders to help students understand the classification, terminology, and pathophysiology of neoplasms and the laboratory's role in diagnosis and therapy. As a part of this section, we included a chapter on stem cell transplantation (Chapter 29) because it is a frequently used therapy for these neoplasms and the laboratory plays a critical role in harvesting the stem cells and preparing them for transplant. Molecular studies are becoming a major diagnostic tool for neoplastic disorders and are discussed within each chapter as well as in the chapter devoted to molecular diagnostics (Chapter 42). Some instructors might prefer to cover Section Eight, the study of bone marrow (Chapter 38), flow cytometry (Chapter 40), cytogenetics (Chapter 41), and molecular diagnostics (Chapter 42) before teaching Section Five or integrate this material with Section Five. Some hematology courses do not include these topics, or instructors might not want to cover them in the depth presented in this book.

Section Six (Chapter 30) is a study of body fluids from a hematologic perspective and thus includes a large number of photographs of cells found in body fluids. Discussions of semen analysis and amniotic fluid lamellar body counts are included. Not all hematology courses include this topic, but the chapter is written in such a way that it can be used separately in a body fluid course.

Section Seven (Chapters 31–36) is a study of hemostasis. Chapters on normal hemostasis include primary and secondary hemostasis and fibrinolysis. They are followed by three chapters on disorders of hemostasis. Chapter 36 describes the testing procedures for hemostasis, including information on automation. This chapter describes an extensive collection of coagulation procedures.

Section Eight (Chapters 37–42) includes chapters on test procedures that help in the diagnosis of hematologic disorders. Automation in hematology is included in Chapter 39. Chapter 42 is designed to introduce molecular procedures and their use in detecting various hematologic and hemostatic disorders. A background in genetics is suggested before students begin this chapter.

Section Nine (Chapter 43) is a thorough discussion of quality assessment in the hematology laboratory. Problems discussed include common abnormal results, errors, and alert flags. Corrective action to take to resolve these problems is described. Several excellent tables help to quickly find needed information. We suggest that these tables be read early in the course of study because they can be used periodically when attempting to interpret and correlate laboratory test results. Chapter 10 refers the reader to these tables because it discusses interpretation of test results and abnormalities in the CBC.

Appendices collect additional information including step-by-step procedures for some hematology testing, and reference tables.

The text emphasizes the effective, efficient, and ethical use of laboratory tests. The clinical laboratory professional

is in an ideal position to assist physicians in interpreting laboratory test results and choosing the best reflex tests to arrive at a diagnosis or evaluate therapy. Many laboratories develop algorithms to assist in these tasks. This text includes several algorithms that some laboratories use.

Suitable for all Levels of Learning

The book is designed for both MLT and MLS students. Using only one textbook for both levels is beneficial and economic for laboratory science programs that offer both levels of instruction. It also is helpful for programs that have developed articulated MLT to MLS curricula. The MLS program can be confident of the MLT's knowledge in hematology without doing a time-consuming analysis of the MLT course. In addition, this book is expected to be a great resource for students in on-line courses and for instructors who teach using this format.

Objectives are divided into two levels: Level I (basic) and Level II (advanced). MLT instructors who reviewed the objectives for this text generally agreed that most Level I objectives are appropriate for the MLT body of knowledge. They also indicated that some Level II objectives are appropriate for MLTs. MLS students should be able to meet both Level I and Level II objectives in most cases. If the MLS program has two levels of hematology courses—Level I and Level II—this book can be used for both.

All instructors, regardless of discipline or level, need to communicate to their students what is expected of them. They might want their students to find the information in the text that allows them to satisfy selected objectives, or they might assign particular sections to read. If not assigned specific sections to read, the MLT students may read more than expected, which is not a bad thing!

The design of the text is such that each chapter is divided into modules and each objective is identified with the module that addresses it. These objectives are divided into Level 1 and Level 2. There are two levels of review questions at the end of each module and chapter that are matched to the two levels of objectives. Case Study questions and the Checkpoints are included within each module and are appropriate for the information in that module or another previous module. Checkpoints and case study questions are not delineated by level. Students should use these valuable resources to assess their understanding of the material.

We recognize that there are many approaches to organizing a hematology course and that not all instructors teach in the same topic sequence or at the same depth. Thus, we encourage instructors to use the book by selecting appropriate chapters and objectives for their students based on their course goals. Each program should assess what content fits its particular curriculum. The layout of the book is such that instructors can select the sequence of chapters

in an order that fits their course design, which might not necessarily be the sequence in the book. However, we recommend that the course begin with Sections One and Two and that the chapters “Introduction to Anemia” and “Introduction to Hematopoietic Neoplasms” be studied before the individual chapters that follow on these topics. The Background Basics sections help the instructor determine which concepts students should master before beginning each chapter. This feature helps instructors customize their courses. Some hematology courses might not include some chapters on subjects such as molecular techniques, cytogenetics, flow cytometry, and body fluids but they might be helpful in other courses.

As a note, this text uses “mc” as an abbreviation for “micro”, which replaces μ . Thus, abbreviations of mcg, mL, mM replace those that use the Greek letter “mu” (μ g, μ L, μ M).

Unique Pedagogical Features

As in the past, the text has a number of unique pedagogical features to help the students assimilate, organize, and understand the information. Each chapter begins with a group of components intended to set the stage for the content to follow.

- The **Objectives** comprise two levels: Level I for basic or essential information and Level II for more advanced information. Each instructor should guide students to the appropriate level to meet course expectations.
- The **Key Terms** feature alerts students to important terms used in the chapter and found in the glossary. With this digital version, these terms are provided as links within the chapter, giving the student the definition within the glossary.
- The **Background Basics** component alerts students to material that they should have learned or reviewed before starting the chapter. In most cases, this feature links readers to previous chapters to help them find the material if they want to review it.
- The **Case Study** is a running scenario that first appears at the beginning of a chapter, giving a patient’s clinical and laboratory information that is related to the chapter content. It is meant to focus the students’ attention on the chapter subject matter. At appropriate places throughout the chapter additional information on the case is provided, such as additional laboratory test results, followed by questions that relate to the material presented in preceding sections. The answers are provided after the student submits the answers.
- The **Overview** gives readers an idea of the chapter content and organization.
- **Checkpoints** are integrated throughout the chapter to help the student determine if they understand what

they just read. They are questions that require students to pause along the way to recall or apply information covered in preceding sections. The answers are provided after the student submits their answer.

- A **Summary** concludes the text portion of each chapter to help students bring all the material together.
- **Review Questions** appear at the end of each chapter. The two sets of questions, Level I and Level II, are referenced and organized to correspond to the Level I and Level II objectives. Answers are provided in the Appendix.
- Image Atlas

The page design features a number of enhancements intended to aid the learning process.

- **Figures and tables** are used liberally to help students organize and conceptualize information. This is especially important for visual learners.
- **Microphotographs** are displayed liberally in the book and are typical of those found in a particular disease or disorder. Students should be aware that cell variations occur and that blood and bone marrow findings do not always mimic those found in textbooks. Because there is so much variation in the morphology of normal and abnormal cells, we added a Flash Card review of additional cells at the end of many chapters. The legend for each microphotograph gives the original magnification but sometimes the image was zoomed to enhance detail.

Appendices

- Appendix A contains tables of reference intervals for common hematology test results.
- The table in Appendix B was extensively revised and updated consistent with the WHO 2017 classification of hematopoietic and lymphoid tissue through a collaborative effort of several authors (Drs. Kathleen Wilson, Katalan Keleman, Sara Taylor, and Tim Randolph). It lists hematopoietic neoplasms with the following information on each: immunophenotype using CD markers, cytogenetic abnormalities, and genotypic findings. This table provides a ready reference for information from the chapters in Section Five (Neoplastic Hematologic Disorders) and Section 8 (Hematology Procedures).
- Appendix C is a comprehensive classification of hematopoietic, lymphopoietic, and histiocytic/dendritic neoplasms using the updated 2017 WHO classification.
- Appendix D is a collection of common laboratory procedures that are linked from Chapter 37 where the procedure is discussed. These can be printed and used in hematology laboratory courses.

- Appendix E provides the answers to the multiple choice questions that appear at the end of each chapter.
- Appendix F provides the answers to the Checkpoint questions that appear throughout each chapter.
- Appendix G provides the answers to the Case Study questions that appear throughout each chapter.

A Complete Teaching and Learning Package

A variety of ancillary materials designed to help instructors be more efficient and effective and students more successful complements this book.

An **Instructor's Resource Center** is available upon adoption of the text and gives the instructor access to a number of powerful tools in an electronic format. The following materials are downloadable:

- The **TestGen** feature includes questions to allow instructors to design customized quizzes and exams. Download the TestGen desktop application and test bank, choose questions that align to your textbook, and generate your test — it's that easy!
- The **PowerPoint Lectures** tool contains key discussion points and color images for each chapter. This feature provides dynamic, fully designed, integrated lectures that are ready to use, allowing instructors to customize the materials to meet their specific course needs. These ready-made lectures will save instructors time and allow an easy transition into using *Clinical Laboratory Hematology*.
- The **Image Library** feature contains all of the images from the text. Instructors have permission to copy and paste these images into PowerPoint lectures, printed documents, or website as long as they are using *Clinical Laboratory Hematology* as their course textbook.
- The **Instructor's Resource Manual** tool in Word formats can be accessed.

Acknowledgments

Writing a textbook is a complicated task that requires a team of dedicated authors, editors, copy editors, artists, permission researchers, educators, practitioners, content reviewers, project and program managers, and many other individuals behind the scenes. The team that Pearson and the editors put together to make the fourth edition of this book an excellent hematology and hemostasis resource for students and health care practitioners worked tirelessly over several years to bring the project to completion. Dr. Kristin Landis-Piwowar envisioned how the mechanics of this new digital "book" could lend to a pioneering form of medical laboratory science education. The new and returning authors ensured that their chapters were up to date and accurate. Content

reviewers and users of the previous editions provided helpful suggestions that were incorporated into the chapters. Dave Falleur, Diana Cochran-Black, Muneez Esani, Sara Wagner, Holly Weinberg, and Linda Whaley had important roles in reviewing select chapters. We offer our thanks to this group who ensured a quality textbook for a wide audience.

Mark Cohen from Pearson was responsible for the creation of the first edition of this text. His keen insights into developing a unique textbook design with pedagogical enhancements helped *Clinical Laboratory Hematology* become a leading textbook in the field of clinical laboratory science. Thank you, Mark. Thank you, Pearson, for having faith in us to publish a fourth edition in digital format. Thank you for creating and providing the special team of experts to help us accomplish this task. We recognize that the job is not over but will require the efforts of sales and marketing to ensure widespread use and adoption. John Goucher had the foresight to develop the fourth edition and for the background work that identified and justified the need for a digital version. He had faith in us and provided support and encouragement for another edition of *Clinical Laboratory Hematology*.

Michael Giacobbe was the Pearson man behind the scenes who kept the entire process moving forward. He also on-boarded authors for support materials including PowerPoints, test questions, and the instructor's manual. This group of author educators, Elizabeth Warning, MS, MLS(ASCP)^{CM}, University of Cincinnati; Joshua J. Cannon, MS, MLS(ASCP)^{CM}, Thomas Jefferson University; and Holly Weinberg, BS, MLS(ASCP)^{CM}, contributed behind the scenes to enhance the instructors' use of this book. Thank you all for your timely assistance. Ellen Viganola, Digital Project Manager for Pearson did a great job transferring the manuscript from print to digital.

Development editor, Barbara Price was our daily contact who kept us on track even though it meant multiple deadline revisions. This was especially challenging as we moved from a paper copy to a digital version of the book. Her gentle prodding was evident and appreciated. Her editing was superb. Dan Knott, Editorial Project Manager, and Prathiba Rajagopal, Senior Project Manager, both from SPI Global, kept track of the many people, files and technical elements involved in bringing the book to the digital realm.

Sara Wagner and John Landis contributed countless hours of scanning slides and taking pictures to produce an incredible image atlas that accompanies this fourth edition. John Landis lead the compiling, organizing, and editing of the atlas images and as well as other microphotographs in the book.

Maggie Sera carefully reviewed and edited the references in this edition. Her attention to detail and sleuthing skills were imperative to ensuring that we presented our citations properly.

I have enjoyed the unique opportunity to edit four editions of *Clinical Laboratory Hematology* with Pearson. As our knowledge in hematology has expanded, many new tests have been developed to help diagnose hematologic diseases. Likewise, the number of authors and editors needed to cover this material has increased. My thanks go out to all hematologists who have contributed over the years to make this text a leader for MLS/MLT education and practice. I am privileged to work with my brilliant coeditors, Lynne and Kristin. Thank you to Kristin for the superb job you have done in creating, editing, and authoring, especially the image atlas. I couldn't have found a better replacement. Thank you to my colleague and friend Dr. J. Lynne Williams for her dedication to this process in the last several editions. Her sharp eyes, superb writing talent and keen mind are essential traits for an editor. We have similar philosophies about teaching hematology and often discussed how to best present the information in this book and make it better.

During the time this book was under development, my professional life took over many hours of my personal life. Many thanks to my husband and best friend Gary for his support, sacrifices, and understanding during some very stressful times so this edition could become a reality. My sincerest gratitude to my parents, George and Helen Olson, who instilled in me the confidence that I could accomplish anything I set my heart to. This mind-set has stuck with me through life, especially in this task. I hope that through example I have provided the same to my children and grandchildren.

SBM

I am thankful to those who helped to build my fire. My father, John Landis, guided me into medical laboratory science and became my hematology professor. My fascination with blood cells was sparked by my dad. Lynne Williams provided me the opportunity of an academic position and encouraged me to participate in the third edition of this book; Lynne has kindled my professional work. As digital natives, my students have taught me how they learn in the technology era. They inspired my vision and pursuit of a novel means to teach hematology through technology; these past students are my energizing air. The foundation of this book is the ingenuity of Shirlyn McKenzie who has dedicated her life to educating generations of budding hematologists. Because she entrusted me as editor, Shirlyn is my flame.

I am also thankful to those who sustained my fire. My husband, Todd, and my children, Theron and Kaia, are the glowing embers that supported my fire when my professional endeavors intersected with my personal life. And my mother, whose empowering spirit, eternal energy, and helping hands keep my blaze roaring. I wouldn't be half of who I am without my family.

My gratitude is endless to you all.

KLP

I extend a special thank you to my colleagues in the Clinical and Diagnostic Sciences program at Oakland University—Dr. Sumit Dinda, Dr. Bekah Martin, Lisa DeCeuninck, Terese Trost, and Bill Van Dyke, and our many part-time instructors—who kept the programs moving forward while we were working on this new edition and to the CDS students of the past 2 years who tolerated a distracted and often absent-minded professor. To all my former students: You have been my inspiration to try to create a meaningful and useful book to support your educational endeavors. But special thank you to my co-editors, Dr. Shirlyn McKenzie, for the privilege of accompanying you on this wonderful journey through these three editions together, and Dr. Kristin Landis-Piwowar, who has been a major guiding force and visionary for this new e-edition book.

JLW

Reviewers

LINDA L. BREIWICK, BS, CLS(NCA), MT(ASCP)
Program Director, Medical Laboratory Technology
Shoreline Community College
Seattle, WA

LINDA COMEAUX, BS, CLS(NCA)
Vice-President for Instruction
Red Rocks Community College
Lakewood, CO

MONA GLEYSTEN, MS, CLS(NCA)
Program Director, Medical Laboratory Technician
Program
Lake Area Technical Institute
Watertown, SD

ANNA SWANN, MS, MLS (ASCP)^{CM}
The University of Southern Mississippi
Hattiesburg, MS

Contributors

GRACE B. ATHAS, PhD
Assistant Professor, Department of Pathology
Louisiana State University, School of Medicine
New Orleans, LA
Chapter 16

CHERYL BURNS, MS, MLS(ASCP)^{CM}
Distinguished Teaching Professor
Department of Health Sciences, Medical Laboratory
Sciences
School of Health Professions
University of Texas Health Science Center at San Antonio
San Antonio, TX
Chapters 37, 39, 43

MICHELLE BUTINA, PhD, MLS(ASCP)^{CM}

Associate Professor, Department of Pathology, Anatomy,
and Laboratory Medicine
West Virginia University, School of Medicine
Morgantown, WV
Chapter 9

**DIANA L. COCHRAN-BLACK, DR PH, MLS(ASCP)^{CM},
SH(ASCP)^{CM}**

Associate Professor and Chair, Medical Laboratory Sciences
Program
Wichita State University
Wichita, KS
Chapter 17

FIONA E. CRAIG, MD

Professor of Pathology, Division of Hematopathology
Department of Laboratory Medicine and Pathology
Mayo Clinic Arizona
Phoenix, AZ
Chapters 28, 40

AAMIR EHSAN, MD

Chief, Pathology and Laboratory Medicine
South Texas Veterans Health Care System
Associate Professor, Department of Pathology
University of Texas Health Science Center at San Antonio
San Antonio, TX
Chapters 29, 38

MUNEEZA ESANI, PhD, MPH, MHA, MT(ASCP)

Assistant Professor, Clinical Laboratory Science
University of Texas Medical Branch
Galveston, TX
Chapter 12

DEBORAH E. FOX, PhD, MT (ASCP)

Associate Professor and Director, Medical Laboratory
Science Program
Franciscan Missionaries of Our Lady University
Baton Rouge, LA
Chapter 13

ROBERT C. GOSSELIN, CLS

Hemophilia Treatment Center
Division of Hematology/Oncology
UC Davis Health System
Sacramento, CA
Chapter 36

KRISTLE HABERICHTER, DO

Anatomic and Clinical Pathology
Grand Traverse Pathology, PLLC
Traverse City, MI
Chapter 38

JOEL D. HUBBARD, PhD, MLS(ASCP)

Associate Professor, Laboratory Sciences and Primary Care

Texas Tech University Health Science Center, School of
Health Professions
Lubbock, TX
Chapters 5, 15

KATALIN KELEMEN, MD, PhD

Consultant, Department of Pathology and Laboratory
Medicine
Associate Professor of Pathology
Mayo Clinic Arizona
Phoenix, AZ
Chapters 28, 40

GIDEON H. LABINER, MS, MLS(ASCP)^{CM}

Associate Professor, Medical Laboratory Science
Program
University of Cincinnati
Cincinnati, OH
Chapter 23

JOHN H. LANDIS, MS, MLS(ASCP)

Professor Emeritus, Ferris State University
Canadian Lakes, Michigan
Adjunct Professor, University of Cincinnati
Chapter 10

KRISTIN LANDIS-PIWOWAR, PhD, MLS(ASCP)^{CM}

Associate Professor, Clinical and Diagnostic Sciences
Associate Dean, School of Health Sciences, Oakland
University
Rochester, MI
Chapters 2, 7, 10, 21

SALLY S. LEWIS, PhD, MLS (ASCP), HTL, MB

Associate Dean and Professor, College of Health Sciences
and Human Services
Tarleton State University
Stephenville, TX
Chapter 42

DAVID L. MCGLASSON, MS, MLS(ASCP)^{CM}

Retired Clinical Research Scientist
59th Clinical Research Division
Laboratory Services
JBSA Lackland, TX
Chapter 36

SHIRLYN B. MCKENZIE, PhD, MLS(ASCP)^{CM}, SH^{CM}

Distinguished Teaching Professor
Professor Emeritus and Chair Emeritus
Department of Health Sciences, Division of Medical
Laboratory Sciences
School of Health Professions
University of Texas Health Science Center at
San Antonio
San Antonio, TX
Chapters 1, 6, 11, 12

**ROSLYN WOFFORD MCQUEEN, PhD, CCRC,
MT(ASCP), SH**
Clinical Research Coordinator
Hurley Medical Center
Flint, MI
Chapter 22

CATHERINE N. OTTO, PhD, MBA, MLS(ASCP)^{CM}
Associate Professor, Department of Clinical Laboratory
and Medical Imaging Sciences
School of Health Professions
Rutgers, The State University of New Jersey
Newark, NJ
Chapter 11, 43

KEILA POULSEN, BS, MLS(ASCP)^{CM}, H, SH
Hematology and Histology Supervisor
Eastern Idaho Regional Medical Center
Idaho Falls, ID
Chapter 10

TIM R. RANDOLPH, PhD, MT(ASCP)
Associate Professor, Department of Clinical Health Sciences
Saint Louis University
St. Louis, MO
Chapters 14, 24

KYLE B. RIDING, PhD, MLS(ASCP)
Assistant Professor of Medicine
University of Central Florida
Orlando, FL
Chapters 26, 27

STACEY ROBINSON, MS, MLS(ASCP)^{CM}, SH^{CM}
Supervisor, Clinical Microscopy
Walter Reed National Military Medical Center
Bethesda, MD
Chapters 5, 15

ANNETTE SCHLUETER, MD, PhD
Clinical Professor, Department of Pathology
University of Iowa
Iowa City, IA
Chapter 3

LINDA SMITH, PhD, MLS(ASCP)^{CM}, BB
Professor Emeritus, Department of Health Sciences,
Division of Medical Laboratory Sciences
University of Texas Health San Antonio
San Antonio, TX
Chapters 19, 20

JULIE K. SODER, MS, MLS(ASCP)^{CM}
Assistant Professor, Department of Clinical Laboratory
Science
University of Texas Medical Branch
Galveston, TX
Chapter 13

BROOKE L. SOLBERG, PhD, MLS(ASCP)^{CM}
Associate Professor and Chair, Department of Medical
Laboratory Science
University of North Dakota School of Medicine and Health
Sciences
Grand Forks, ND
Chapters 33, 34

JEAN SPARKS PhD, MT(ASCP)
Associate Professor, Department of Life Sciences
Texas A&M University-Corpus Christi
Corpus Christi, TX
Chapter 18

SARA TAYLOR, PhD, MLS(ASCP), MB^{CM}
Associate Professor, Medical Laboratory Science and Public
Health
Tarleton State University
Fort Worth, TX
Chapters 25, 42

SARA L. WAGNER, MLS (ASCP)^{CM}
Instructor of Hematology
Beaumont Health School of Medical Laboratory Science
Royal Oak, MI
Chapters 10, 37, 39

JERELYN WALTERS, MLS(ASCP), SH
Technical Supervisor, Esoteric Testing, ACL Laboratories
Milwaukee, WI
Chapter 30

LINDA WHALEY, MLS
Technical Specialist, Stem Cell Laboratory
Cardinal Bernard Cancer Center
University Medical Center
Loyola University
Chicago, IL
Chapter 29

J. LYNNE WILLIAMS, PhD, MT(ASCP)
Professor and Chair, Clinical and Diagnostic Sciences
Oakland University, School of Health Sciences
Rochester, MI
Chapters 4, 8, 31, 32, 35

KATHLEEN S. WILSON, MD, FCAP, FACMG
Professor, Department of Pathology and The McDermott
Center for Human Growth and Development
Director, Cytogenomic Microarray Analysis Laboratory
University of Texas Southwestern Medical Center
Dallas, TX
Chapter 41

ANDREA C. YUNES, MD
Audie L. Murphy Memorial VA Hospital
San Antonio, TX
Chapter 29, 38

Credits

Chapter 1 Table 1-1 Courtesy of Linda Smith.

Chapter 2 Figure 2-1 From “The fluid mosaic model of the structure of cell membranes” by Singer S J & Nicolson G L in *Science*, Volume 175, Number 46, pp. 720–31. Published by Elsevier, © 1972.

Chapter 3 Figure 3-2 Used by permission of Dr. Corey Parlet. Figure 3-4 a,b Annette Schlueter.

Chapter 5 Figure 5-2 Shirlyn McKenzie. Figure 5-3 Kristin Landis-Piwowar. Figure 5-4 Based on Clinical Expression and Laboratory Detection of Red Cell Membrane Protein Mutations by J. Palek and P. Jarolim in *SEMINARS IN HEMATOLOGY* 30(4): 249–283, October 1993. Published by W.B./Saunders Co., an imprint of Elsevier Health Science Journals. Table 5-1 images Shirlyn McKenzie.

Chapter 6 Figure 6-8 MCMURRY, JOHN; CASTELLION, MARY E.; BALLENTINE, DAVID S.; *FUNDAMENTALS OF GENERAL, ORGANIC, AND BIOLOGICAL CHEMISTRY*, 5th ED., © 2007. Reprinted and Electronically reproduced by permission of Pearson Education, Inc., Upper Saddle River, New Jersey. Figure 6-9 Based on Principles of Biochemistry, 4E by H. R. Horton, L. A. Moran, K. G. Scrimgeour and M. D. Perry. Published by Pearson Education, Inc., © 2006.

Chapter 7 Figures 7-1; 7-2; 7-3; 7-4; 7-10; 7-11a-c; 7-12; 7-13; Table 7-3 images Shirlyn McKenzie.

Chapter 8 Table 8-3 images Shirlyn McKenzie.

Chapter 9 Figures 9-1; 9-2a,b; 9-3a,b; 9-4; 9-5 Shirlyn McKenzie.

Chapter 10 Figures 10-1; 10-2; 10-4a; 10-5a-c; 10-7; 10-9; 10-11; 10-13; 10-14; 10-15; Table 10-10 images 1-4 Shirlyn McKenzie. Figure 10-3 Roche Diagnostics Hematology. Figures 10-4b,c; 10-12 John H. Landis. Figures 10-6; 10-8a,b; 10-10; Table 10-7 images; Table 10-10 image 5; Case Study images Kristin Landis-Piwowar.

Chapter 11 Figure 11-1 Shirlyn McKenzie. Figure 11-2 Roche Diagnostics Hematology. Tables 11-3, 11-4, 11-5, 11-6 From Morbidity And Mortality Weekly Report. Published by Centers for Disease Control.

Chapter 12 Figures 12-11; 12-13a,b; 12-14; 12-15; 12-17 Shirlyn McKenzie.

Chapter 13 Table 13-1 Data from Huisman, T.H., Carver, M.F., Baysal, E., & Efremov, G. D. (2017). et al. A Database of Human Hemoglobin Variants and Thalassemias [Data file]. Retrieved from <http://globin.cse.psu.edu/globin/hbvar/menu.html>. Figures 13-3, 13-4, 13-5, 13-w6, 13-7 Shirlyn McKenzie.

Chapter 14 Figures 14-4a,b; 14-5; 14-8; 14-9; 14-11; 14-12; 14-13; 14-14 Shirlyn McKenzie. Table 14-8 Data from Maria Stella Figueiredo (2015) The Compound state: Hbs/Beta. *Thalassemia*, Rev Brass Hemtol Hemotes 37(3). 150–152; Ngo DA et.al.(2011) Fetal Heameoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin and deletional hereditary persistence of fetal haemoglobin, 156:259–264; Fucharoen S, et.al. (2003) Interaction of haemoglobin and several forms of thalassemia in combidian families 88(10) 1092–1098.

Chapter 15 Figure 15-1b Kristin Landis-Piwowar. Figures 15-1a; 15-03; 15-04a,b; 15-11 Shirlyn McKenzie.

Chapter 16 Figure 16-1 Shirlyn McKenzie.

Chapter 17 Figure 17-1 Pearson Education, Inc. Figures 17-2; 17-4; 17-5; 17-6; 17-7; 17-8; 17-9 Shirlyn McKenzie.

Chapter 18 Figures 18-2; 18-4; 18-6 Shirlyn McKenzie.

Chapter 19 Figures 19-4; 19-5 Shirlyn McKenzie.

Chapter 20 Figures 20-2; 20-3; F20-4a-c Shirlyn McKenzie. Figure 20-5 John H. Landis.

Chapter 21 Figures 21-1; 21-2; 21-3a,b; 21-4; 21-5; 21-7; 21-8; 21-9; 21-10a,b; 21-11; 21-12; 21-13; 21-14; 21-15; 21-16; 21-17 Shirlyn McKenzie. Figure 21-6 John H. Landis.

Chapter 22 Figures 22-1; 22-2; 22-3; 22-4; 22-5 Shirlyn McKenzie. Table 22-6 From MMWR Recommendations and Reports: Past Volume: 63(RR-03):1–10. Published by Centers for Disease Control and Prevention.

Chapter 23 Figures 23-2; 23-3 Shirlyn McKenzie.

Chapter 24 Figures 24-2; 24-5; 24-6; 24-7; 24-8; 24-9; 24-10; 24-12; 24-13; 24-14 Shirlyn McKenzie. Table 24-14 Data from Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, LeBeau MM, Bloomfield CD, Cazzola M, and Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20);2391–2405.

Chapter 25 Figures 25-1; 25-2; 25-3; 25-4; 25-5; 25-6; 25-7; 25-8; 25-09a,b; 25-11a,b; 25-12 Shirlyn McKenzie.

Chapter 26 Figures 26-2a,b; 26-3; 26-4; 26-5; 26-6; 26-7a,b; 26-08a,b Shirlyn McKenzie.

Chapter 27 Figures 27-1a,b; 27-2a,b Shirlyn McKenzie.

Chapter 28 Figures 28-2; 28-5d; 28-7; 28-11a; 28-12a,b; 28-13 Fiona Craig. Figures 28-1a,b; 28-3a,b; 28-4a-d; 28-5a-c; 28-6a,b; 28-8; 28-9a-c; 28-10a,b; 28-11b-d; 28-14; 28-15a-c; Shirlyn McKenzie.

Chapter 29 Figures 29-1; 29-2a,b Dr. Aamir Ehsan.

Chapter 30 Table 30-2 Data from Morgenstern LB, Luna-Gonzales H, Huber JC et al. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. *Ann Emerg Med*. 1998;32:297–304; Julia-Sanchis ML. Rapid differential

diagnosis between subarachnoid hemorrhage and traumatic lumbar puncture by D-dimer assay. *Clin Chem.* 2007;53:993. Figures 30-5; 30-6; 30-7; 30-59a,b; 30-60; 30-62; 30-63; 30-64; 30-65; 30-66; 30-67 Jerelyn Walters. Figures 30-8 through 30-31; 30-33 through 30-58; 30-68 through 30-71 Shirlyn McKenzie.

Chapter 31 Figures 31-7a-d Shirlyn McKenzie.

Chapter 33 Figures 33-02a-c; 33-7 Shirlyn McKenzie.

Chapter 37 Figures 37-1; 37-2; 37-3; 37-4; 37-5; 37-9; 37-18 Cheryl Burn. Figures 37-10; 37-20; 37-22; 37-25; 37-30 Shirlyn McKenzie. Figures 37-6 Tracey C. Webb. Figures 37-29; 37-31; 37-32; 37-33; 37-34; 37-35; 37-36; 37-37 Dr. Aamir Ehsan. Figures 37-23; 37-24 Courtesy of Helena Laboratories.

Chapter 38 Figures 38-2; 38-3; 38-4; 38-5a-c; 38-6; 38-7; 38-8 Shirlyn McKenzie.

Chapter 39 Figure 39-1 From Seminar and Case Studies: The Automated Differential by Pierre R. Copyright © 1985 by Beckman Coulter, Inc. Figures 39-2; 39-3; 39-6 From Significant Advances in Hematology. Copyright © 1983 by Beckman Coulter, Inc. Figure 39-4 From Red Cell


Distribution Parameters – (1) RDW – SD (2) RDW (CV), Technical Bulletin 9617. Copyright © 1983 by Beckman Coulter, Inc. Figures 39-11; 39-12; 39-13; 39-14 From Advancements in Technology: WBC Differential Methodology, Technical Bulletin 9403. Copyright © 2009 by Beckman Coulter, Inc. Figures 39-9; 39-16; 39-17; 39-18; 39-21; 39-25; 39-26 Shirlyn McKenzie.

Chapter 41 Figures 41-5; 41-6; 41-10 Shirlyn McKenzie. Figure 41-4 NiMedia/Shutterstock.

Chapter 43 Table 43-6 From Abbott Laboratories. Used by permission of Abbott Laboratories.


Appendix C Modified with permission from Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

Glossary Clinical and Laboratory Standards Institute (CLSI) entry is Copyright by Clinical and Laboratory Standards Institute.



Section One

Introduction to Hematology



Chapter 1

Introduction

Shirlyn B. McKenzie, PhD



Objectives—Level I and Level II

At the end of this unit of study, the student should be able to:

1. Compare the reference intervals for hemoglobin, hematocrit, erythrocytes, and leukocytes in infants, children, and adults.
2. Identify the function of erythrocytes, leukocytes, and platelets.
3. Describe the composition of blood.
4. Explain the causes of change in the steady state of blood components.
5. Describe reflex testing, and identify the laboratory's role in designing reflex testing protocols.
6. Define hemostasis and describe the result of an upset in the hemostatic process.
7. Identify hematology and hemostasis screening tests.
8. List the three components of laboratory testing and correlate errors with each component.
9. Define value-based health care and give an example of how the laboratory can assist in building the value agenda.

Chapter Outline

Objectives—Level I and Level II 2

Key Terms 3

Background Basics 3

Case Study 3

Overview 3

Introduction 3

Composition of Blood 4

Reference Intervals for Blood Cell Concentration 4

Hemostasis 5

Blood Component Therapy 5

Investigation of a Hematologic Problem 6

The Value of Laboratory Testing 6

Summary 7

Review Questions 7

References 8

Key Terms

Activated partial thromboplastin time (APTT)	Hematopoiesis	RBC indices
Complete blood count (CBC)	Hemoglobin	Red blood cell (RBC)
Diapedese	Hemostasis	Reflex test
Erythrocyte	Leukocyte	Serum
Hematocrit	Plasma	Thrombocyte
Hematology	Platelet	White blood cell (WBC)
	Prothrombin time (PT)	

Background Basics

Students should complete courses in biology and physiology before beginning this study of hematology.

CASE STUDY

We refer to this case study throughout the chapter.

Aaron, a 2-year-old male, was seen by his pediatrician because he had a fever of 102–104 °F over the past 24 hours. Aaron was lethargic. Before this, he had been in good health except for two episodes of otitis.

Consider why the pediatrician might order laboratory tests and how this child's condition might affect the composition of his blood.

Overview

Hematology is the study of blood and blood-forming organs. The hematology laboratory is one of the busiest areas of the clinical laboratory. Even small, limited-service laboratories usually offer hematology tests. This chapter is an introduction to the composition of blood and the testing performed in the hematology laboratory to identify the presence and cause of disease.

Introduction

Blood has been considered the essence of life for centuries. One of the Hippocratic writings from about 400 B.C. describes the body as being a composite of four humors: black bile, blood, phlegm, and yellow bile. It is thought that the theory of the four humors came from the observation that four distinct layers form as blood clots *in vitro*: a dark-red, almost black, jellylike clot (black bile); a thin layer of oxygenated red cells (blood); a layer of white cells and

platelets (phlegm); and a layer of yellowish serum (yellow bile).¹ Health and disease were thought to occur as a result of an upset in the equilibrium of these humors.

The cellular composition of blood was not recognized until the invention of the microscope. With the help of a crude magnifying device that consisted of a biconvex lens, Antonie van Leeuwenhoek (1632–1723) accurately described and measured the **red blood cells** (also known as **RBCs** or **erythrocytes**). The discovery of **white blood cells** (also known as **WBCs** or **leukocytes**) and **platelets** (also known as **thrombocytes**) followed after microscope lenses were improved.

As a supplement to these categorical observations of blood cells, Karl Vierordt, in 1852, published the first quantitative results of blood cell analysis.² His procedures for quantification were tedious and time consuming. After several years, many others attempted to correlate blood cell counts with various disease states.

Improved methods of blood examination in the 1920s and the increased knowledge of blood physiology and blood-forming organs in the 1930s allowed anemias and other blood disorders to be studied on a rational basis. In some cases, the pathophysiology of hematopoietic disorders was realized only after the patient responded to experimental therapy.

Contrary to early hematologists, modern hematologists recognize that alterations in the components of blood are the *result* of disease, not a *primary cause* of it. Under normal conditions, the production of blood cells in the bone marrow, their release to the peripheral blood, and their survival are highly regulated to maintain a steady state of morphologically normal cells. Quantitative and qualitative hematologic abnormalities can result when an imbalance occurs in this steady state.

Composition of Blood

Blood is composed of a liquid called **plasma** and of cellular elements, including leukocytes, platelets, and erythrocytes. After blood coagulates, the resulting liquid component is called **serum**. The normal adult has about 6 liters of this vital fluid, which composes from 7% to 8% of the total body weight. Plasma makes up about 55% of the blood volume; about 45% of the volume is composed of erythrocytes, and 1% of the volume is composed of leukocytes and platelets. Variations in the quantity of these blood elements are often the first sign of disease occurring in body tissues. Changes in diseased tissue may be detected by laboratory tests that measure deviations from normal in blood constituents. Hematology is primarily the study of the formed cellular elements of the blood.

The principal component of plasma is water, which contains dissolved ions, proteins, carbohydrates, fats, hormones, vitamins, and enzymes. The principal ions necessary for normal cell function include calcium, sodium, potassium, chloride, magnesium, and hydrogen. The main protein constituent of plasma is albumin, which is the most important component in maintaining osmotic pressure. Albumin also acts as a carrier molecule, transporting compounds such as bilirubin and heme. Other blood proteins carry vitamins, minerals, and lipids. Immunoglobulins, synthesized by lymphocytes, and complement are specialized blood proteins involved in immune defense. The coagulation proteins responsible for **hemostasis** (arrest of bleeding) circulate in the blood as inactive enzymes until they are needed for the coagulation process. An upset in the balance of these dissolved plasma constituents can indicate a disease in other body tissues.

Blood plasma also acts as a transport medium for cell nutrients and metabolites; for example, the blood transports hormones manufactured in one tissue to target tissue in other parts of the body. Albumin transports bilirubin, the main catabolic residue of hemoglobin, from the spleen to the liver for excretion. Blood urea nitrogen, a nitrogenous waste product, is carried to the kidneys for filtration and excretion. Increased concentration of these normal catabolites can indicate either increased cellular metabolism or a defect in the organ responsible for their excretion. For example, in liver disease, the bilirubin level in blood increases because the liver is unable to function normally and clear the bilirubin. In hemolytic anemia, however, the bilirubin concentration can rise because of the increased metabolism of hemoglobin that exceeds the ability of a normal liver to clear bilirubin.

When body cells die, they release their cellular constituents into surrounding tissue. Eventually, some of these constituents reach the blood. Many constituents of body cells are specific for the cell's particular function; thus, increased concentration of these constituents in the blood, especially

enzymes, can indicate an abnormal increase in cell destruction in a specific organ.

Blood cells are produced and develop in the bone marrow. This process is known as **hematopoiesis**. Undifferentiated hematopoietic stem cells (precursor cells) proliferate and differentiate under the influence of proteins that affect their function (cytokines). When the cell reaches maturity, it is released into the peripheral blood.

Each of the three cellular constituents of blood has specific functions. Erythrocytes contain the vital protein **hemoglobin**, which is responsible for transport of oxygen from the lungs to the body tissues. Erythrocytes also facilitate the transport of carbon dioxide from the tissues back to the lungs. The five major types of leukocytes are neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Each type of leukocyte has a role in defending the body against foreign pathogens such as bacteria and viruses. Platelets are necessary for maintaining hemostasis. Blood cells circulate through blood vessels, which are distributed throughout every body tissue. Erythrocytes and platelets generally carry out their functions without leaving the vessels, but leukocytes **diapedese** (pass through intact vessel walls) to tissues where they defend against invading foreign pathogens.

CASE STUDY *(continued from page 3)*

1. If Aaron was diagnosed with otitis media, what cellular component(s) in his blood would be playing a central role in fighting this infection?

Reference Intervals for Blood Cell Concentration

Physiologic differences in the concentration of cellular elements can occur according to race, age, sex, and geographic location; pathologic changes in specific blood cell concentrations can occur as the result of disease or injury. The greatest differences in reference intervals occur between newborns and adults. In general, newborns have a higher erythrocyte concentration than any other age group. The erythrocytes are also larger than those of adults. In the 6 months after birth, erythrocytes gradually decrease in number and then slowly increase. Hemoglobin and erythrocyte counts increase in children between the ages of 5 and 17. The leukocyte concentration is high at birth but decreases after the first year of life. A common finding in young children is an absolute and relative lymphocytosis (increase in lymphocytes). After puberty, males have higher hemoglobin, **hematocrit** (packed red blood

cell volume in whole blood), and erythrocyte levels than females. The hemoglobin level decreases slightly after age 70 in males. This is thought to be due to the decrease in testosterone. Appendix D, Tables A through J give hematologic reference intervals for various age groups and by sex if appropriate.

Each individual laboratory must determine reference intervals of hematologic values to account for the physiologic differences of a population in a specific geographical area. Reference intervals for a hematologic parameter are determined by calculating the mean ± 2 standard deviations for a group of healthy individuals. This interval represents the reference interval for 95% of normal individuals. A value just below or just above this interval is not necessarily abnormal; normal and abnormal overlap. Statistical probability indicates that about 5% of normal individuals will fall outside the ± 2 standard deviation range. The further a value falls from the reference interval, however, the more likely the value is to be abnormal.

CASE STUDY (continued from page 4)

Aaron's physician ordered a complete blood count (CBC). The results are Hb 11.5 g/dL; Hct 34%.

2. What parameters, if any, are outside the reference intervals? Why do you have to take Aaron's age into account when evaluating these results?

Hemostasis

Hemostasis is the property of the circulation that maintains blood as a fluid within the blood vessels and the

system's ability to form a barrier (blood clot or thrombus) to prevent excessive blood loss when the vessel is traumatized, limit the barrier to the site of injury, and dissolve the thrombus to ensure normal blood flow when the vessel is repaired. Hemostasis occurs in stages called *primary* and *secondary hemostasis* and *fibrinolysis* (breakdown of fibrin). These stages are the result of interaction of platelets, blood vessels, and proteins circulating in the blood. An upset in any of the stages can result in bleeding or abnormal blood clotting (thrombosis). Laboratory testing for abnormalities in hemostasis is usually performed in the hematology section of the laboratory; occasionally, hemostasis testing is performed in a separate specialized section of the laboratory.

Checkpoint 1.1

What cellular component of blood can be involved in disorders of hemostasis?

Blood Component Therapy

Blood components can be used in therapy for various hematologic and nonhematologic disorders. Whole blood collected from donors can be separated into various cellular and fluid components. Only the specific blood component (i.e., platelets for thrombocytopenia or erythrocytes for anemia) needed by the patient will be administered. In addition, the components can be specially prepared for the patient's specific needs (i.e., washed erythrocytes for patients with IgA deficiency to reduce the risk of anaphylactic reactions). Table 1-1 lists the various components that can be prepared for specific uses.

Table 1.1 Blood Components and Their Uses

Component Name	Composition	Primary Use
Whole blood	Red blood cells and plasma	Not used routinely; can be used in selected trauma, autologous transfusions, and neonatal situations; increases oxygen-carrying capacity and volume
Packed red blood cells (PRBCs)	PRBCs	Used in individuals with symptomatic anemia to increase oxygen-carrying capability
PRBCs, washed	PRBCs; plasma with most leukocytes and platelets removed	Used for individuals with repeated allergic reactions to components containing plasma and for IgA-deficient individuals with anaphylactic reactions to products containing plasma
PRBCs, leukoreduced	PRBCs; WBC removed	Used to decrease the risk of febrile nonhemolytic transfusion reaction, HLA sensitization, and cytomegalovirus (CMV) transmission
PRBCs, frozen, deglycerolized	PRBCs frozen in cryoprotective agent, thawed, washed	Used for individuals with rare blood groups (autologous donation)
PRBCs, irradiated	PRBCs with lymphocytes inactivated	Used to reduce the risk of graft-versus-host disease
Platelets, pooled ^a	4–6 units of random donor platelets	Used to increase platelet count and decrease bleeding when there is a deficiency or abnormal function of platelets
Platelets, single ^a donor (pheresis)	Equivalent of 4–6 donor platelets collected from single donor	Used to treat patients refractory to random platelet transfusion or to increase platelet count due to a deficiency or abnormal function of platelets

(Continued)

Table 1.1 Blood Components and Their Uses (*Continued*)

Component Name	Composition	Primary Use
Fresh frozen plasma (FFP)	Plasma with all stable and labile coagulation factors; frozen within 8 hours of collection of unit of blood	Used to treat patients with multiple coagulation factor deficiencies; disseminated intravascular coagulation (DIC); used with packed RBC in multiple transfusions
Cryoprecipitated AHF ^b	Concentrated FVIII, fibrinogen, FXIII, von Willebrand factor	Used to treat patients with hypofibrinogenemia, hemophilia A, von Willebrand's disease, FXIII deficiency
Plasma, cryo-poor	Plasma remaining after cryo removed	Used to treat thrombotic thrombocytopenic purpura (TTP)
Liquid plasma	Plasma not frozen within 8 hours of collection	Used in patients with deficiency of stable coagulation factor(s) and for volume replacement
Granulocytes	Granulocytes	Used to treat the neutropenic patient who is septic and unresponsive to antimicrobials and who has chance of marrow recovery

^a Platelets can also be leukoreduced or irradiated. See PRBC for reasons.

^b Cryoprecipitated antihemophilic factor.

Courtesy of Linda Smith, Ph.D., MLS(ASCP)^{CM}; adapted from the *circular of information for the use of human blood and blood components*. Prepared jointly by the American Association of Blood Banks, America's Blood Centers, and the American Red Cross (2002).

Investigation of a Hematologic Problem

Laboratory testing is divided into three components: pre-examination, examination, and post-examination (formerly known as preanalytical, analytical, postanalytical). The *pre-examination* component includes all aspects that occur prior to the testing procedure that affect the test outcome such as phlebotomy technique and transport and storage of the specimen after it is drawn but before the test is run. The *examination phase* refers to all aspects affecting the test procedure. The *post-examination* component includes all aspects after the testing is completed such as reporting of results and execution of appropriate clinical responses. These three aspects of testing are the backbone of a quality assessment program. See Chapters 10 and 43 for a detailed description of these three phases.

A physician's investigation of a hematologic problem includes taking a medical history and performing a physical examination. Clues provided by this preliminary investigation help guide the physician's choice of laboratory tests to help confirm the diagnosis. The challenge is to select appropriate tests that contribute to a cost-effective and efficient diagnosis. Laboratory testing usually begins with screening tests; based on results of these tests, more specific tests are ordered. The same tests can be ordered again on follow-up to track disease progression, evaluate treatment, identify side effects and complications, or assist in prognosis.

Hematology screening tests include the **complete blood count (CBC)**, which quantifies the WBCs, RBCs, hemoglobin, hematocrit, and platelets, and the **RBC indices** (Chapter 10). The indices are calculated from the results of the hemoglobin, RBC count, and hematocrit to define the size and hemoglobin content of RBCs. The indices are important parameters used to differentiate causes of anemia and help

direct further testing. The CBC can also include a WBC differential. This procedure enumerates the five types of WBCs and reports each as a percentage of the total WBC count. A differential is especially helpful if the WBC count is abnormal. When the count is abnormal, the differential identifies which cell type is abnormally increased or decreased and determines whether immature and/or abnormal forms are present, thus providing a clue to diagnosis. The morphology of RBCs and platelets is also studied as a routine part of the differential and reported if abnormal. The assessment of RBC morphology can provide key information to a differential diagnosis and help guide the selection of additional tests for a definitive diagnosis.³

If a hemostasis problem is suspected, the screening tests include the platelet count, **prothrombin time (PT)**, and **activated partial thromboplastin time (APTT)** (Chapter 36). The PT and APTT tests involve adding calcium and thromboplastin or partial thromboplastin to a sample of citrated plasma and determining the time it takes to form a clot. These tests provide clues that guide the choice of follow-up tests to help identify the problem.

The Value of Laboratory Testing

The "value agenda" of health care advocates is achieving the best outcomes at minimal cost without sacrificing quality.⁴ In 2011, the Centers for Medicare and Medicaid Services (CMS) announced a reimbursement model intended to increase the accountability for achieving the best patient outcomes at minimal cost without sacrificing quality of care.⁵ The focus is on population health management versus a fee for service based on volume. By 2014, 20% of Medicare reimbursement shifted to value-based payment models that

directly link reimbursement to the health and well-being of patients. The goal is to have 50% of Medicare payments in these value-based payment models by 2018. The laboratory can play a major role in creating and advancing the value agenda by improving clinical outcomes through the use of appropriate laboratory testing while helping payers hold down costs (economic outcomes).

Follow-up testing that is done based on results of screening tests is referred to as **reflex testing**. These testing protocols are sometimes referred to as *algorithms*. Follow-up tests can include not only hematologic tests but also chemical, immunologic, microbiologic, and/or molecular analysis. As scientists learn more about the pathophysiology and treatment of hematologic disease and hemostasis, the number of tests designed to assist in diagnosis expands and, without testing guidelines, the cost can increase due to inappropriate and unnecessary test selection. Errors in selection of the most appropriate laboratory tests and interpretation of results can result in misdiagnosis or treatment errors and is a major source of poor patient outcomes. Laboratory professionals can assist in promoting good patient outcomes by assisting physicians and patient care teams in selecting the most efficient and effective testing strategies^{6,7,8} through development of test ordering protocols and assisting in interpretation of test results.⁹ Furthermore, validation studies of algorithms may help determine if a particular testing protocol is better

than others in helping diagnose or follow effectiveness of treatment. Readers are urged to use the reflex testing and algorithm concepts in their thought processes when studying the laboratory investigation of a disease.

In an effort to help the student gain the knowledge to perform these functions, in this text each hematologic disorder is discussed in the following order: etiology, if known, pathophysiology, clinical presentation, laboratory evaluation, and therapy. The reader should consider which laboratory tests provide the information necessary to identify the cause of the disorder based on the suspected disorder's pathophysiology. Although it is unusual for the physician to provide a patient history or diagnosis to the laboratory when ordering tests, this information is often crucial to direct investigation and assist in interpretation of the test results. In any case, if laboratory professionals need more patient information to appropriately perform testing, they should obtain the patient's chart or call the physician.

Checkpoint 1.2

A 13-year-old female saw her physician for complaints of a sore throat, lethargy, and swollen lymph nodes. A CBC was performed with the following results: Hb 9.0 g/dL; Hct 30%; WBC $15 \times 10^3/\text{mL}$. On the basis of these results, should reflex testing be performed?

Summary

Hematology is the study of the cellular components of blood: erythrocytes, leukocytes, and platelets. Physiological changes in the concentrations of these cells occur from infancy until adulthood. Diseases can upset the steady state concentration of these parameters. A CBC is usually performed as a screening test to determine whether there are quantitative abnormalities in blood cells. The physician

can order reflex tests if one or more of the CBC parameters are outside the reference interval. Platelet count, PT, and APTT are screening tests for disorders of hemostasis.

Changes in the health care system focus on containing costs while maintaining quality of care. The laboratory's role in this system is to work with physicians to optimize utilization of laboratory testing.

Review Questions

Level I and Level II

- In which group of individuals would you expect to find the highest reference intervals for hemoglobin, hematocrit, and erythrocyte count? (Objective 1)
 - Newborns
 - Males older than 12 years of age
 - Females older than 17 years of age
 - Children between 1 and 5 years of age
- Which cells are important in transporting oxygen and carbon dioxide between the lungs and body tissues? (Objective 2)
 - Platelets
 - Leukocytes
 - Thrombocytes
 - Erythrocytes

3. Forty-five percent of the volume of blood is normally composed of: (Objective 3)
 - a. erythrocytes
 - b. leukocytes
 - c. platelets
 - d. plasma
4. Alterations in the concentration of blood cells generally are the result of: (Objective 4)
 - a. laboratory error
 - b. amount of exercise before blood draw
 - c. a disease process
 - d. variations in analytical equipment
5. Leukocytes are necessary for: (Objective 2)
 - a. hemostasis
 - b. defense against foreign pathogens
 - c. oxygen transport
 - d. excretion of cellular metabolites
6. Laboratories can use which type of testing to help direct the physician's selection of appropriate testing after screening tests are performed? (Objective 5)
 - a. Reflexive based on results of screening tests
 - b. Manual repeat of abnormal results
 - c. Second test by a different instrument
 - d. Standing orders for all inpatients
7. Screening tests used to evaluate the hemostasis system include: (Objective 6)
 - a. PT and APTT
 - b. CBC
 - c. hemoglobin
 - d. WBC count
8. A patient blood specimen is stored in a car for 2 hours with the outside temperature of 95 °F. This is an example of error in which component of testing? (Objective 8)
 - a. Pre-examination
 - b. Examination
 - c. Post-examination
9. The value of laboratory medicine can be increased by: (Objective 9)
 - a. providing raw data to payers when asked
 - b. prompting physicians to use a testing algorithm for anemia diagnosis
 - c. focusing on fee for service based on increasing testing volume.
 - d. not interfering with physician test ordering

References

1. Wintrobe, M. M. (1980). *Blood: Pure and eloquent*. New York: McGraw-Hill.
2. Vierordt, K. (1852). Zahlungen der Blutkörperchen des Menschen. *Archives of Physiology Heilk*, 11, 327.
3. Ford, J. (2013). Red blood cell morphology. *International Journal of Laboratory Hematology*, 35(3), 351–357.
4. Hillary, W., Justin, G. L., Bharat, M., & Jitendra, M. (2016). Value based healthcare. *Advances in Management*, 9(1), 1–8.
5. Center for Medicare and Medicaid Services (CMS). Department of Health and Human Services. Final Rule. (2011). Medicare program; Hospital inpatient value-based purchasing program. *Federal Register*, 76(88), 26489–26547.
6. Hernandez, J. S. (2003). Cost-effectiveness of laboratory testing. *Archives of Pathology and Laboratory Medicine*, 127, 440–445.
7. From, P., & Barak, M. (2012). Cessation of dipstick urinalysis reflex testing and physician ordering behavior. *American Journal of Clinical Pathology*, 137(3), 486–489.
8. Feldman, L. S., Shihab, H. M., Thiemann, D., Yeh, H. C., Ardolino, M., Mandell, S., & Brotman, D. J. (2013). Impact of providing fee data on laboratory test ordering. *JAMA Internal Medicine*, 173(10), 903–908.
9. Dighe, A. S., Makar, R. S., & Lewandrowski, K. B. (2007). Medicolegal liability in laboratory medicine. *Seminars in Diagnostic Pathology*, 24(2), 98–107.



Chapter 2

Cellular Homeostasis

Kristin Landis-Piwozwar, PhD



Objectives—Level I

At the end of this unit of study, the student should be able to:

1. Describe the location, morphology, and function of subcellular organelles of a cell.
2. Describe the lipid asymmetry found in the plasma membrane of most hematopoietic cells.
3. Differentiate DNA replication, transcription, translation, and DNA repair.
4. Differentiate the parts of the mammalian cell cycle.
5. Define R (*restriction point*) and its role in cell-cycle regulation.
6. Define *apoptosis* and explain its role in normal human physiology.
7. Classify and give examples of the major categories of initiators and inhibitors of apoptosis.
8. List the major events regulated by apoptosis in hematopoiesis.



Objectives—Level II

At the end of this unit of study, the student should be able to:

1. Explain the significance of SNPs, introns, exons, UTRs, and post-translational protein modifications.
2. List the components and explain the function of the ubiquitin-proteasome system.
3. Define *cyclins* and *Cdks* and their role in cell-cycle regulation; describe the associated Cdk partners and function of cyclins D, E, A, and B.
4. Define the two major classes of CKIs (cyclin-dependent kinase inhibitors) and describe their function.
5. Compare the function of cell-cycle checkpoints in cell-cycle regulation.
6. Describe/illustrate the roles of p53 and pRb in cell-cycle regulation.
7. Propose how abnormalities of cell-cycle regulatory mechanisms can lead to malignancy.